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                                                   INTRODUCTION 
 
Renal failure is an important medical complication for which patients 
are admitted in medical wards.  Renal failure is classified as Acute Renal 
Failure (ARF) and Chronic Kidney Disease (CKD).  ARF is a reversible renal 
disease, while CKD is an irreversible renal disease. 
 
On admission, it may be difficult to diagnose ARF or CRF and further 
evaluation is required to confirm the diagnosis.  In our Hospital, these patients 
were admitted in the Medical Units, Nephrology Department or the Intensive 
Medical Care Unit.  In this study patients admitted and diagnosed to have renal 
failure in medical units only were analysed. Acute diarrheal disease is the most 
common cause of ARF. Chronic glomerulonephritis is the most common cause 
of CKD which was closely followed by Diabetic Nephropathy. The study was 
done in Stanley Medical college Hospital, which is located in North Chennai. 
This study deals with etiological, clinical and laboratory profile of renal 
failure. 
 
 
 
                                                 2 
AIM OF THE STUDY 
 
1. To evaluate the type of renal failure (ARF/CKD) admitted in the 
medical units. 
2. To analyse the etiology, clinical features and management of ARF. 
3. To analyse the etilogy, clinical feature and management of CKD. 
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ACUTE RENAL FAILURE 
 
ARF is a syndrome characterized by rapid decline of glomerular 
filtrarion rate (hours to days), retention of nitrogenous waste products and 
pertubation of extracellular fluid volume and electrolyes and acid base 
homeostasis1.ARF complicates 2- 5% of hospital admission and 30% of ICU 
admissions1,2. Most ARF are reversible. 
 
The manifestations of ARF are subtle. Losing the function of one half of 
the nephron mass(1 million glomeruli) will cause creatinine levels to rise from 
about 0.7 mg/dL upto only about 1.4 mg/dL2. Oliguria (urine output < 400ml/d 
) is the commonest clinical feature  (50%). ARF is usually asymptomatic and 
diagnosed when biochemical monitoring of hospitalized patients shows an 
increase in blood urea and creatinine concentration. The ADQI (Acute Dialysis 
Quality Initiative) evolved the RIFLE classification, which grades ARF 
according to severity (Risk, Injury, Failure) and outcome (Loss and End stage 
disease). 
 
The RIFLE system 
 
The term Acute Kidney Injury if preferred to Acute renal failure3. Plasma 
creatinine and or urine volume indicate kidney function.  A change in baseline    
S. creatinine reflects the severity of ARF.  
• RISK - S.creatinine increases 1.5 times or GFR decreases by >25% and 
fall of GFR occurs in  6 hours 
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• INJURY- S.creatinine increases 2 times or GFR decreases by >50% 
and fall of GFR occurs in  12 hours 
• FAILURE- S.creatinine increases 3 times or GFR decreases by >75% 
and fall of GFR occurs in  24  hours or anuria for > 12 hours or  S 
creatinine     > 4 mg/dL 
• LOSS- persistent ARF, complete loss of kidney function for >4 weeks 
• ESKD- End stage kidney disease for > 3 months 
 
ARF is divided into three categories: 
1. PRERENAL ARF (50%) - Diseases that cause renal hypoperfusion 
without affecting renal parenchyma 
2. INTRINSIC RENAL ARF (40%) - Diseases that affect renal 
parenchyma. 
3. POSTRENAL ARF (5%)- Diseases causing urinary tract obstruction 
 
PRERENAL ARF 
It is the most common form of ARF. It is a physiologic response to 
renal hypoperfusion due to a decrease in effective arterial blood volume. 
Decreased effective circulating volume may result from volume depletion, 
peripheral vasodilatation or low cardiac output. Prerenal ARF is rapidly 
reversible upon restoration of renal blood flow and glomerular ultrfiltration 
pressure. There is no damage to renal parenchyma. 
 
 5 
ETIOLOGY OF PRERENAL ARF 
 
1. HYPOVOLUMIA 
a) hemorrhage, burns, dehydration 
b) gastrointestinal fluid loss- vomiting, diarrhea, surgical drainage 
c) sequestration of fluid in extravascular space- pancreatitis, peritonitis 
2. LOW CARDIAC  OUTPUT 
Diseases of myocardium, valves, pericardium, cardiac arrythmias, tamponade. 
 
3. ALTERED RENAL SYSTEMIC VASCULAR RESISTANCE RATIO 
a) Systemic vasodilatation- sepsis, anaphylaxis 
b) Renal vasoconstriction- hypercalcemia, epinephrine, norepinephrine, 
cyclosporine, tacrolimus. Amphotericin B 
c) Cirrhosis with ascites- hepatorenal syndrome 
4. HYPERVISCOSITY SYNDROMES 
Multiple myeloma, macroglobinemia, polycythemia. 
 
PATHOGENESIS OF PRERENAL ARF 
Autoregulation occurs maximally at mean systemic arterial B.P of 80 mm 
Hg. Further fall in B.P leads to decline in GFR leading to ARF. Drugs affecting 
the compensatory mechanisms may connvert compensated renal hypoperfusion to 
Prerenal ARF or trigger progression of Prerenal ARF to Ischemic intrinsic renal 
ARF. These drugs cause inhibition of prostglandin synthesis like NSAIDS, ACEI 
and ARB. NSAIDS precipitate prerenal ARF in  patients with hypovolumia. 
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In patients with bilateral renal artery stenosis or unilateral stenosis with 
single kidney, the GFR is solely dependant on Angiotensin II . Therefore 
Angiotensin II blockers will precipitate ARF in these patients.  
 
In prerenal states the kidney avidly retains sodium, usually resulting in 
low urine sodium and fractional excretion of sodium (FENa) of less than 1%. 
Other conditions where FENa >1% may be observed are radiocontrast induced 
renal failure, AGN, liver failure, pigment induced nephrotoxicity, early 
obstructive nephropathy, vasculitis and normal renal function.  
FENa is calculated as follows: 
FENa = [( UNa X Pcr)/( PNa X Ucr)] X 100    
Where U= Urine and P= Plasma4. 
 
ETIOPATHOGENESIS OF INTRINSIC RENAL FAILURE 
1. Acute tubular necosis 
a) ischemic- etiology same as prerenal ARF( hypovolumia, low cardiac 
output, systemic vasodilation) or by obstetric complications              
(abruptio placentae, postpartum hemorrhage) 
b) Toxins 
Endogenous toxins- rhabdomyolysis, hemolysis, uric acid, oxalates 
Exogenous toxins – radiocontrast, cyclosporine, antibiotics 
2. Diseases of the Glomeruli or renal vasculitis. 
a) glomerulonephritis- PIGN, MPGN, RPGN and vascilitides 
 7 
b) hemolytic uremic syndrome, TTP, DIC, Toxemia of pregnancy, 
Accelerated hypertension, radiation nephritis, SLE, Scleroderma 
3. Interstitial Nephritis 
a) Allergic- Antibiotics ( β lactums, sulphonamides, trimethoprim, 
rifampicin), NSAIDS, Diuretics, captopril, cimentidine, thiazides 
b) Infections- acute pyelonephritis, leptospirsis, candidiasis 
c) Lymphoma, leukemia, sarcoidosis. 
4. Renovascular obstruction 
a) Renal Artery obstruction- atherosclerotic plaques, thrombosis, 
embolism, vasculitis. 
b) Renal vein obstruction- thrombosis, compression.  
5. Intratubular deposition and obstruction- myeloma protein, uric acid, 
oxalate, acyclovir, Methotrexate, sulphonamides 
6. Renal allograft rejection. 
 
ACUTE TUBULAR NECROSIS (ATN) 
ATN is the most common form of intinsic ARF. Prerenal azotemia is 
the soil that nurtures ATN. In ischemic ARF, hypoperfusion induces ischemic 
injury to renal parenchymal cells, particularly tubular epithelium and recovery 
takes 1 to 2 weeks after normalisation of renal perfusion as it requires repair 
and regeneration of renal cells5.  
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ATN has four phases. 
1. Initiation phase (1-12 hours) - This begins when renal blood flow 
decreases resulting in cellular ATP depletion which trigger pathways to 
sub lethat cell injury or cell death. 
2. Extension phase (10- 60 hours) - this is characterised by   
a) continued hypoxia of the outer nmedulla due to intra renal 
vasoconstriction by Angiotensin  II, Endothelin-1, decreased NO 
b) stasis and accumulation of RBC’s and WBC’s in the outer medullary 
vessels 
c) endothelial damage leading to continued ischemia 
d) promotion of coagulation in peritubular vessels 
e) inflammatory injury due to activation of inflammatory cascade 
Renal injury can be limited by restoration of blood flow during this 
period. 
 
3. Maintenance phase - Renal blood flow returns to near normal. The 
tubular cells undergo apoptosis, proliferation, dedifferentiation, 
migration and re-establish strctural integrity. GFR stabilises and stays 
low (5-10 mL/min) because of intra renal vasoconstriction, urine output 
is lowest and uremic complications arise. 
4. Recovery phase - characterized by repair and regeneration of tubule 
epithelial cell and gradual return of GFR to near normal. This phase 
may be complicated by a marked diuretic phase. 
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NEPHROTOXIC ARF 
The incidence of Nephrotoxic ARF is increased in elderly,   in patients 
with chronic renal insufficiency. Intrarenal vasoconstriction is the main event in 
radiocontrast nephropathy.  Volume depletion, multiple myeloma, heart failure 
and age >65 years are risk factors. The ARF is oliguric and S.creatinine peaks in 
the first 72 hours after exposure. Renal functions recover in 7-10 days.  
Aminoglycoside nephrotoxicity occurs in 10-30% of the courses of 
aminoglycosides, even in therapeutic levels. It is most often nonoliguric and is 
caused by direct toxicity to the tubule epithelial cells4. The other drugs are 
acyclovir,foscarnet, amphotericin B, pentmidine and chemotherapeutic agents like 
cisplatin, carboplatin and ifosfamide. 
The most common endogenous toxins are calcium, myoglobin, 
hemoglobin, urate, oxalate and myeloma light chains. Hypercalcemia causes 
intrarenal vasoconstriction and calcium deposition within the kidney.  
Myoglobinuria with ARF complicates 30% of cases of Rhabdomyolysis like 
traumatic crush injury, seizures, excessice exercise, heat stroke, alcohol 
intoxication, cocaine intoxication and infectious or metabolic disorders.   
It is associated with muscle pain, increased uric acid, hyperkalemia, 
hyperphosphatemia and increased level of creatine kinase(MM isoenzyme). ARF 
due to hemolysis follows massive blood transfusion reactions. They cause ARF by 
direct toxicity to tubule epithelial cells, inducing intratubular cast formation,  
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causing intrarenal vasoconstriction by inhibiting nitric oxide bioactivity. Both 
hemolysis and rhabdomyolysis induce ARF especially in acidotic and 
hypovolemic individuals.  
In ARF with multiple myeloma, intratubular casts containing 
immunoglobulin light chains and other proteins are formed and cause myeloma 
cast nephropathy. Light chains are also directly toxic to the tubule epithelial 
cells. Acute uric acid nephropathy complicates treatment of 
lymphoproliferative are myeloproliferative disorders causing intratubular 
precipitation of massive amounts of uric acid. 
Certain drugs induce ARF by triggering allergic interstitial nephritis. 
There is infiltration of the tubulointerstitium by granulocytes (mostly 
eosinophils), macrophages and lymphocytes. AIN presents as sudden onset of 
azotemia in association with signs of generalized drug reaction or with 
septicemia or malignant infiltration of the kidney. Interstitial edema, intense 
patchy or diffuse cellular infiltration and relatively well-preserved glomeruli 
and tubules characterize renal histology. Eosinophilic infiltration occurs early 
but disappears rapidly. The chance of finding eosinophiluria is dependent upon 
the timing of urinalysis6. 
Patients with atherosclerosis can develop ARF due to embolization of 
cholesterol crystals to the renal vasculature. They also have retinal arteriolar 
plaques, lower extremity livedo reticularis and necrosis in distal digits4. 
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Acute GN can result in ARF. RPGN presents with an acute 
deterioration of renal function, nephrotic or non-nephrotic proteinuria and 
active urinary sediment with hematuria and RBC casts. Oliguria may be 
present. RPGN can be further characterized by the presence of immune 
complex deposition (SLE, poststreptococcal GN, IgA nephropathy, 
endocarditis), the paucity of immune complex deposition (Wegener’s 
granulomatosis, microscopic polyangitis,        Churg-Strauss syndrome) or the 
presence of anti-GBM disease.  
MALARIAL ARF 
The renal failure sets within 5-7 days after the onset of fever. The most 
important histopathological abnormality was ATN. The factors contributing to 
tulular injury are hypovolemia, intravascular hemolysis, intravascular 
coagulation, septicemia, catecholamine release and haemo-rheological changes 
induced by parasitized erythrocytes7,8.  
LEPTOSPIRAL ARF 
The pathogenesis of renal failure is leptospirosis is multifactorial and 
may include hypoxia secondary to hypovolemia/hypotension and direct 
nephrotoxicity due to toxic by-products of leptospires9. Body fluid loss due to 
vomiting,  
increased insensible water losses and diminished intake of fluid are responsible 
for hypovolemia and hypotension in some cases. In the kidney, leptospires 
initially cause glomerular injury and by hematogenous spread, the organisms  
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reach peritubular capillaries and migrate to the interstitium, renal tubules and 
tubular lumen causing interstitial nephritis and tubular necrosis10. 
 
POST RENAL ARF 
This accounts for less than 5% of the case of ARF. ARF from 
Obstruction requires obstruction to urine flow between the external urethral 
meatus and bladder neck, bilateral ureteric obstruction or unilateral ureteric 
obstruction in a patient with single functioning kidney. The presence of 
alternating anuria and polyuria is classic occurence in urinary tract obstruction.  
Urinary tract obstructions may be within the urinary tract (eg. Blood clots, 
stones, sloughed papillae or fungal balls) or extrinsic (eg tumors, 
retroperitoneal fibrosis or even inadvertent ligation). Bladder neck obstruction 
is the most common cause of post-renal ARF and is commonly due to prostatic 
diseases, neurogenic bladder or treatment with anticholinergics. During the 
early stages of obstruction, continued glomerular filtration leads to increased 
intraluminal pressure upstream to the site of obstruction. As a result there is 
gradual distention of the proximal ureter, renal pelvis, calyces and a fall in 
GFR.. 
 
CLINICAL FEATURES OF ARF 
Prerenal ARF has symtoms such as thirst and dizziness and physical 
evidence of orthostatic hypotension and tachycardia, reduced JVP, decreased  
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skin turgor, and dry mucus membranes. History of recent initiation of 
treatment with NSAIDS, ACE inhibitors or angiotensin II blockers should be 
sought.  
Intrinsic renal ARF follows severe renal hypoperfusion complicating 
hypovolemic or septic shock or following major surgery. 
Postrenal ARF presents with suprapubic and flank pain due to distention 
of the bladder and renal collecting system. Colicky flank pain radiating to the 
groin suggests acute ureteric obstruction. Neurogenic bladder should be 
suspected in patients receiving anticholinergics or with physical evidence of 
autonomic dysfunction.  
Complications of ARF include expansion of ECF volume with 
pulmonary edema, hyperkalemia, hyperphosphatemia, metabolic acidosis, 
anemia and uremic syndrome. 
 
INVESTIGATIONS IN ARF 
 
URINALYSIS 
Anuria suggests complete urinary tract obstruction or severe intrinsic or 
prerenal ARF. PH is acidic in prerenal ARF and alkaline in obstructive 
uropathy. Glucosuria without hyperglycemia suggests severe proximal 
convoluted tubule damage.  
Hyaline casts are found in prerenal ARF. Hyaline casts are formed from 
Tamm-Horsfall protein, which is secreted by epithelial cells of the loop of 
Henle. 
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Pigmented “muddy brown” granular casts are characteristics of ATN. 
There will be associated microscopic hematuria and mild tubular proteinuria. 
RBC casts indicate glomerular injury. White cell casts and nonpigmented 
granular casts suggest interstitial nephritis. Eosinophiluria (> 5% urine 
leukocytes) occurs in antibiotic-induced allergic interstitial nephritis. 
Eosinophiluria also occurs in atheroembolic ARF.  
Minimal proteinuria occurs in prerenal and obstructive disorders. 
Glomerulonephritis causes selective albuminuria whereas ATN, AIN and post-
renal ARF cause nonselective proteinuria. Light chain proteinuria as in 
multiple myeloma causes neagative distick test for protein but gives a positive 
flocculation test. Positive reaction for blood occurs in hemoglobinuria and 
myoglobinuria. If the urine is heme positive but the serum is not pink red, 
myoglobinuria is suggested. Red pink plasma suggests hemoglobinuria6. 
 
LABORATORY FINDINGS 
Hyperuricemia, hyperkalemia, hyperphosphatemia with increased levels 
of LDH indcates acute urate nephropathy and tumor lysis syndrome. A wide 
serum anion and osmolal gap indicates ethylene glycol or methanol ingestion. 
Systemic eosinophilia occurs in allergic interstitial nephritis, atheroembolic 
disease and polyangitis nodosa. Ultrasound is useful to exclude postrenal ARF. 
Retrograde or antegrade pyelography helps to identify the site of obstruction. 
Doppler ultrasound and magnetic resonance angiography are useful to assess  
 15 
the patency of renal arteries and veins. Renal biopsy is reserved for patients in 
whom pre renal and post renal ARF have been excluded and the cause of 
intrinsic renal failure is unclear.  
 
MANAGEMENT OF ARF 
FLUID MANAGEMENT 
Fluid replacement should be equal to insensible losses plus urinary and 
other drainage losses. Hyponatemia in patients with ARF is usually secondary 
to volume expansion with hypotonic fluid, whereas hypernatremia is caused by 
overly aggressive diuresis.  Fluid challenge can be given in oliguric patietns 
who are not volume overloaded. Around 500-1000 ml of normal saline is 
infused over 30-60 min.  
 
DIETARY MODIFICATION 
Total calorie intake should be 35-50 kcal/kg/d. Salt intake should be 
restricted to 2-4 g/d. Potassium intake should be restricted to 40 mEq/d and 
Phosphorus intake should be restricted to 800 mg/d.  
Patients at risk for radiocontrast nephropathy should be well hydrated 
with 75-150 ml/hour of 0.45% saline beginning 12-24 hours before the contrast 
study and ending 12 hours after the study. Acetylcysteine (600 mg PO bid; 4 
doses total, starting 1 day before the procedure) reduces the incidence and 
severity of contrast nephropathy11. 
 16 
In rhabdomyolysis aggressive fluid administration should be initiated to 
replace fluid that is lost into the necrotic muscle and to establish high urine flow. 
Alkalinization of the urine(urine PH >6.5) by iv infusion of 2-3 ampoules of 
NaHCO3 in 1 L of 5% dextrose in water increases the solubility of heme 
pigments and will hasten recovery. 
In acute uric acid nephropathy, uric acid production is decreased by 
administration of allopurinol 600 mg PO before cytotoxic therapy followed by 
100-300 mg/day. Forced alkaline diuresis helps to prevent uric acid 
precipitation4. 
A one-week course of prednisone 60 mg PO once daily will hasten the 
recovery in drug induced acute interstitial nephritis. Acute glomerulonephritis or 
vasculitis may respond to glucocorticoids, alkylating agents and plasmapheresis. 
Control of systemic hypertension is essential in malignant hypertensive 
nephrosclerosis, toxemia of pregnancy and other vascular diseases. 
Antihypertensives that do not decrease renal blood flow (clonidine, prazosin, 
calcium channel blockers) are used for controlling hypertension.  
Leptospirosis is treated with Penicillin G 1.5 million units 6th hourly and 
Doxycycline 100 mg twice daily9. Malaria is treated with Chloroquine 25 mg/kg 
or quinine 10 mg/kg 8th hourly. 
Obstruction of urethra or bladder neck is usually managed by 
transurethral or suprapubic placement of a bladder catheter. Ureteric obstruction 
is initially treated by percutaneous catheterization of the dilated renal pelvis or 
ureter.  
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Obstructing lesions may be removed percutaneously (calculus, sloughed 
papilla) or bypassed by insertion of a ureteric stent (carcinoma). 
 Hyperkalemia is treated calcium gluconate, insulin, glucose, 
bicarbonate, potassium binding resins. Hyperkalemia that is resistant to 
medical therapy is an indication for urgent dialysis. Metabolic acidosis is 
treated with sodium bicarbonate. 
 
DIALYSIS 
Hemodialysis and Peritoneal dialysis appear equally effective in the 
management of ARF. The dialysis modality is chosen according to the needs of 
individual patients. Peritoneal dialysis is preferable if the patient is 
hemodynamically unstable. The indications for dialysis are uremic syndrome, 
refractory hypervolemia, hyperkalemia and acidosis. 
 
PROGNOSIS 
Mortality rates vary according to the cause of ARF. It is around 60% 
following trauma or major surgery, 30% in toxin related ARF and 15% in 
obstetric patients. 50% of the patients who survive an episode of ARF have 
subclinical impairment of renal function. 5% of patients never recover function 
and require long term renal replacement with dialysis or transplantation1. 
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COMPARISON OF ETIOLOGICAL DATA 
 
The following studies were done  by the Department of Nephrology, 
Madras medical college, during 1979-84, 1987-91, 1995-2004 and the change 
in the etiological profile of ARF  in South India were analysed12-14. 
 
ETIOLOGY 1979-84 % 1987-91 % 1995-2004 % 
Medical causes  90 87.6 
Leptospirosis 5.3 31 7.5 
Acute diarrheal disease 23.5 30.5 28.6 
AGN 26.2 8.5 9.3 
Snake bite 3.2 4.7 7.8 
Drugs 5.3 5.4 13.4 
Copper sulphate 
poisoning 
11.2 3.4 4.3 
Obstetric causes 8.5 9 8.9 
Surgical causes  1.5 3.4 
 
In all the three studies, acute diarrheal disease remained the most 
common cause of ARF. The incidence of Leptospiral ARF increased to 31% 
during       1987-91,  but has decreased now to 7.5%. Drugs have become the 
second most common cause of ARF, which was mostly due to excessive use of 
over-the-counter analgesics.  Sepsis and malaria have become the emerging 
causes. Despite improvements in antenatal care, obstetric renal failure remains 
a significant cause of ARF. The incidence of Surgical ARF was on the rise. 
The mortality was 19.6% n the recent study, but was 27.8% in the first study 
and 26.4% in the second study. 
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CHRONIC KIDNEY DISEASE 
Chronic kidney disease is a pathophysiologic process lasting for more 
than 3 months, with multiple etiologies, resulting in the inexorable attrition of 
nephron number and function and frequently leading to end stage renal disease 
(ESRD)15.  
Kidney damage is either functional or structural with or without 
reduction in GFR as identified by any one or all of three criteria 
1. Abnormal gross or microscopic pathology 
2. Laboratory markers of kidney damage in blood, urine, imaging tests 
3. GFR < 60 ml/min/1.73 m2 in the absence of any other renal 
abnormality16 
Risk factors for CKD include family history of renal disease, 
hypertension, diabetes, autoimmune diseases, older age, past episode of 
ARF, Systemic infections, Urinary tract infections, Urinary stones, Lower 
urinary tract obstruction, Drugs including NSAID abuses16. 
STAGES OF CKD 
A recently widely accepted international classification divides CKD 
into a number of stages defined by clinical estimation of GFR15. 
STAGE DESCRIPTION GFR, mL/min/1.73m2 
 
1 
At increased risk, kidney damage with 
normal or increased GFR 
90(with CKD 
risk factors) 
2 Kidney damage with mildly decreased GFR 60-89 
3 Moderately decreased GFR 30-59 
4 Severely decreased GFR 15-29 
5 Renal failure <15 
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During stages 1 and 2, patients remain symptom free. As the decline in 
GFR progresses to stages 3 and 4, clinical and laboratory compliations of CKD 
become prominent. Patients may be azotemic and erythropoietin production 
decreases. Abnormalities of calcium and phosphorus metabolism causes 
metabolic bone disease and abnormalities of sodium, water, potassium and 
acid-base homeostasis occurs. When the GFR falls to <15 ml/min/1.73 m2, 
uremia occurs wherein continued survival is dependant upon renal replacement 
therapy (dialysis or transplantation). 
 
ESTIMATION OF GFR 
GFR cannot be measured directly. The most widely used measures of GFR 
are based on the 24 hrs creatinine clearance or serum creatinine concentration. 
GFR can be estimated by one of the two equations shown below: 
a) Cockcroft-Gault Equation 
      (140 – Age) x Body weight (kg) 
Estimated Creatinine clearance (mL/min)   = ────────────────── 
72 x Pcr (mg/dL) 
 
b) Modification of diet in renal disease study (MDRD) 
Estimated GFR (mL/min/1.73 m2)        =      1.86 x  (Pcr) -1.154  x (age) -0.203 
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ETIOLOGY 
Diabetic and hypertensive nephropathy are the leading causes of CKD 
and ESRD. Hypertension is a common cause and consequence of CKD in the 
elderly. Other causes include Nondiabetic glomerular disease (nephritic or 
nephrotic), cystic kidney disease and tubulointerstitial diseases. 
The clinical features of CKD are shown in this table17. 
SYSTEM CLINICAL MANIFESTATIONS 
Electrolytes Edema, hyponatremia, hyperkalemia, metabolic acidosis, 
hyperuricemia, hyperphosphatemia, hypocalcemia 
Gastrointestinal Anorexia, nausea, vomiting, malnutrition 
Cardiovascular Accelerated atherosclerosis, systemic hypertension, pericarditis 
Hematologic Anemia, immune dysfunction, platelet dysfunction 
Musculoskeletal Renal osteodystrophy, muscle weakness, growth retardation in 
children, amyloid arthropathy  
Neurologic Encephalopathy, seizures, peripheral neuropathy 
Endocrine Hyperlipidemia, glucose intolerance caused by insulin resistance, 
amenorrhea and infertility in women, impotence  
Skin Pruritus 
 
 
Pathophysiology of uremia  
The pathogenesis of uremia involves three major mechanisms. They are 
diminished excretion of electrolytes and water, reduced excretion of organic 
solutes, and decreased hormone production18,19 . 
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Diminished excretion of electrolytes and water            
An important function of the healthy kidney is to excrete the electrolytes 
and water generated from dietary intake in order to maintain a steady state in 
which intake and urinary excretion are roughly equal. The number of functioning 
nephrons at the stage of ESRD is so small that urinary excretion cannot achieve a 
level equal to intake. Clinical manifestations include edema and hypertension 
(caused by sodium retention), hyponatremia (resulting from free water retention), 
hyperkalemia, metabolic acidosis, hyperuricemia, and hyperphosphatemia.  
Reduced excretion of organic solutes 
The kidneys excrete a variety of organic solutes, the commonly measured 
ones being urea and creatinine. The excretion of urea and creatinine is not actively 
regulated and the plasma level of these solutes begin to rise with the decline in 
GFR.. 
Decreased hormone production 
 The kidneys normally produce several hormones, including erythropoietin 
and calcitriol (1,25-dihydroxycholecalciferol), the active form of vitamin D. The 
decreased production of these two hormones plays an important role in the 
development of anemia and bone disease respectively. 
Systemic complications of CKD and their treatment  
Uremic syndrome consists of an array of complex symptoms and signs that 
occur when advanced kidney failure prompts the malfunction of virtually every  
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organ system. Patients may have symptoms such as malaise, weakness, 
insomnia and a general feeling of being unwell. Patients may lose their appetite 
and complain of morning nausea and vomiting.   
Electrolyte disturbances 
Sodium balance: Sodium balance remains virtually normal until very late in 
the course of CKD, because the kidney can markedly increase the amount of 
sodium excreted per nephron by reducing tubular sodium reabsorption. Intake 
of large amounts of sodium can easily overwhelm the excretory capacity of the 
failing kidney and result in fluid retention, edema, and hypertension. Likewise, 
if diuretics are used overzealously, the patient may become volume-depleted. 
Clinically evident edema is uncommon until the GFR falls to less than 15 
mL/min/1.73m2. Edema also occurs in patients with glomerular disease and 
significant proteinuria (nephrotic syndrome) and in those with heart failure. 
The cornerstone of treatment of edema (and hypertension) is restriction of 
dietary sodium to a level lower than that recommended for uncomplicated 
hypertension (<100 mEq/day; 2.3 g of sodium or 6 g of salt). 
Thiazide diuretics are usually ineffective if the serum creatinine level is 
greater than 3 mg/dL. Loop diuretics are the agents of choice in patients with 
CKD. Patients with advanced CKD may require doses of furosemide (Lasix) as 
high as 400 mg per day. Lack of response to high doses of loop diuretics often 
is due to noncompliance with dietary sodium restriction.  
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Potassium-sparing diuretics (spironolactone) are contraindicated because of the 
risk of inducing hyperkalemia. 
Potassium balance: Potassium balance and plasma potassium level are also 
maintained until very late in CKD, mainly because of an increase in renal 
excretion of potassium per functioning nephron and an increase in potassium 
output in the stool20. Hyperkalemia may occur in association with dietary 
indiscretion (eg, excessive consumption of chocolate, dried fruits, or bananas), 
use of potassium-containing salt substitutes, increased catabolism (as with 
severe intercurrent illness), or metabolic acidosis. It may also be seen with the 
use of potassium-sparing diuretics, angiotensin-converting enzyme (ACE) 
inhibitors, and nonsteroidal anti-inflammatory drugs (NSAIDs). Patients with a 
serum potassium concentration below 6 mEq/L usually respond to a 
combination of a loop diuretic and a low-potassium diet. Asymptomatic 
patients with a serum potassium level above 6 to 6.5 mEq/L can be treated with 
sodium polystyrene sulfonate, given orally or by colonic enema. Symptomatic 
hyperkalemia, particularly in the presence of electrocardiographic changes, is 
treated with combinations of intravenous calcium gluconate and infusions of 
glucose and insulin with or without bicarbonate. This therapy transiently drives 
potassium into the cells. In patients with kidney failure, dialysis may be 
required.  
Water balance: The ability to concentrate or dilute urine is impaired in 
patients with CKD, which makes them more susceptible to hypernatremia and  
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hyponatremia. Hypernatremia may occur if water consumption is not sufficient 
to replace fluid loss. More commonly, hyponatremia develops in patients with 
CKD because they either drink water or are given hypotonic fluids in excess of 
their ability to excrete water.  
Metabolic acidosis: Most patients with CKD develop metabolic acidosis 
because of their reduced ability to excrete the hydrogen ions. The goal is to 
maintain the serum bicarbonate level above 20 mEq/L. Sodium bicarbonate is  
recommended. Calcium carbonate, which is often used as a phosphate binder, 
can help control acidemia as well.  
Cardiovascular complications 
The most common cause of death in patients with ESRD is 
cardiovascular disease. Increased prevalence of coronary artery disease in 
CKD is both due to traditional risk factors like hypertension, hypervolemia, 
dyslipidemia, sympathetic overactivity and hyperhomocysteinemia and non 
traditional risk factors like anemia, hyperphosphatemia and a state of 
microinflammation that occurs in CKD. The elevated acute phase reactants like 
interleukin 6 and  C-reactive protein contribute to the coronary occlusive 
process15. Myocardial ischemia and left ventricular hypertrophy along with salt 
and water retention in uremia lead to congestive cardiac failure.  
Hypertension almost invariably develops in patients with CKD and is 
usually volume-dependent. The goal is to achieve a blood pressure of less than  
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130/85 mm Hg. Treatment of hypertension includes restriction of dietary sodium 
and use of diuretics. ACE inhibitors are protective in patients with proteinuria .  
Uremic pericarditis was once a common finding but is seen much less often 
today because dialysis is usually started before it appears. Treatment of this 
condition includes intensive dialysis and the use of NSAIDS21. 
Hematologic complications 
 
A normochromic and normocytic anemia develops in most patients when 
the GFR falls below 60 mL/min/1.73 m2. It occurs mainly as a result of 
erythropoietin deficiency and deficiency in iron, folate, or vitamin B12. Correction 
of anemia with erythropoietin results in improved cardiac function, exercise 
tolerance, central nervous system symptoms, appetite, and sexual function. 
Although white blood cell count is usually within normal range when CKD is 
present, the function of these cells may be defective, leading to an increased 
susceptibility to infections. Bleeding tendency occurs due to defective platelet 
function22-23.  
Bone disease 
 
Metabolism of calcium and phosphorus is abnormal in patients with CKD 
and is associated with the development of bone disease. Phosphate retention 
occurs as GFR declines. Both hyperphosphatemia and reduction in the active form 
of vitamin D lead to hypocalcemia. As attempts are made to normalize the serum  
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calcium level, secondary hyperparathyroidism can develops and causes renal 
osteodystrophy, which includes osteitis fibrosa, osteomalacia and adynamic 
bone disease24. Calcium carbonate and calcium acetate are effective phosphate 
binders which also correct hypocalcemia. Vitamin D preparations like 
calcitriol help to suppress the levels of parathormone and correct 
hypocalcemia. 
Neurologic complications 
Cerebrovascular accidents of all types are common in CKD. Uremic 
encephalopathy is  characterized by insomnia, impairment of concentration, 
alterations in usual sleep rhythms, emotional lability and depression. Dialysis 
produces rapid clearing of the mental state and correction of abnormal 
electroencephalographic findings. Generalized motor seizures may also occur 
in patients with advanced kidney failure. A symmetrical polyneuropathy of a 
mixed sensory-motor type also occurs.. Sensory symptoms present first 
(cramps, paresthesias, restless legs). Disturbances in autonomic function may 
cause postural hypotension and impotence25. 
Management of CKD 
Dietary modification includes Protein restriction to 0.6-0.8 g/kg/d of 
high biologic value protein, Potassium restriction to 40 mEq/d, no added salt 
diet and salt restriction to 2-3 g/d, fluid restriction to output plus 500 ml. 
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Anemia is treated with recombinant human erythropoietin 50-100 U/kg 
SC two or three times a week. The management of complications are already 
discussed. 
Renal replacement therapy 
This is indicated for the patients with ESRD. 
Hemodialysis: This works by diffusion of small molecular weight solutes 
across a semi permeable membrane. Fluid removal occurs via ultrafiltration. 
Dialysis is usually performed three times a week. Complications are nausea, 
vomiting, headache, hypotension, bleeding due to anticoagulation used in HD, 
dialysis associated pericarditis. 
Peritoneal dialysis: PD can be used for ARF and ESRD. It uses peritoneum as 
dialysis membrane. Dialysis exchange is performed by infusion of 2 L fluid 
into the peritoneal cavity followed by equilibration period and dialysate 
drainage. Complications include peritonitis, hyperglycemia due to systemic 
absorption of glucose from PD fluid and protein loss. 
Renal transplantation: This offers the patient a lifestyle closest to normal. 
Pretransplantation evaluation of the recipient is done which includes blood 
group compatibility testing and human lymphocyte antigen typing. The 
recipient needs life long immunosuppression to prevent rejection4. 
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PATIENTS AND METHODS 
 
1. Patients aged 13 and above, admitted to the medical units of Government 
Stanley Hospital with Serum Creatinine > 1.5 mg/dl were taken up for the 
study.  They were further subdivided into: 
a. Acute Renal Failure ( ARF ) 
 
b. Chronic Kidney Disease ( CKD ) 
 
 
2. The following criteria were used for selecting patients for ARF and CKD. 
a. ARF 
 
• Patients with Serum Creatinine > 1.5 mg/dl  in whom the renal 
failure was reversible  with treatment 
• Rapid onset of renal failure 
• Normal sized Kidneys 
b. CKD 
 
• Patients with Serum Creatinine > 1.5 mg/dl, whom the renal    
failure was not reversible with treatment 
• Gradual onset of renal failure 
3. Exclusion Criteria 
Patients admitted in Intensive Medical Care Unit and Nephrology 
Department were not taken up for the study.  Patients admitted in the 
IMCU had mostly hospital acquired ARF and it has a high mortality rate 
(40-70%). The nephrology department was a referral centre and patients 
there do not comprise the model of the local population in Chennai. 
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4. The following data were obtained. 
a. Symptoms 
 
• Fever 
• Myalgia 
• Headache 
• Diarrhea 
• Vomiting 
• Giddiness 
• Altered 
Sensorium 
• Dyspnea 
 
• Chest Pain 
• Oliguria 
• Dysuria 
• Hematuria 
• Pedal Edema 
• Facial Puffiness 
• Drug Intake 
 
 
b. Signs 
 
• Pulse Rate (PR) 
• Blood Pressure 
• Elevated Jugular Venous Pressure (JVP) 
• Anemia 
• Jaundice 
• Dehydration 
• Pulmonary Edema 
 
c. The past history of systemic hypertension (SHT), Diabetes Mellitus 
(DM), Diabetic Nephropathy (DN), Chronic Kidney Disease (CKD) & 
Coronary Artery Disease (CAD) and their duration were sought.  
d. The following Investigation were done 
1. Blood Sugar 
2. Renal function tests- Blood urea, Serum Creatinine 
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3. Serum Electrolytes 
4. Complete Hemogram 
5. Urinalysis- Urine albumin 
6. Liver Function Tests 
7. ECG 
8. Chest X-Ray 
9. QBC for Malarial Parasites 
10. MSAT/MAT 
11. Ultrasound Abdomen 
 
e. The treatment strategies involving Conservative Medical Management 
and Renal Replacement Therapies (Peritoneal Dialysis, Hemodialysis) 
were evaluated. 
a. Conservative Management of ARF 
 
• Fluid restriction to < 1 L/d 
• Salt restriction 1-2 g/d 
• Protein 0.6 g/kg/d of high biologic value 
• Potassium free diet 
• Carbohydrate 100 g/d 
• Diuretics 
• Restoring hemodynamic compromise due to fluid loss with 
Intravenous fluids 
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• Specific treatment- Malaria- Chloroquine 25mg/day, C. 
Doxycycline 100 mg twice daily or iv Quinine 10 mg/kg 
8th hourly, Leptospirosis- iv crystalline penicillin     
• Withdrawal of nephrotoxic drugs     
• Forced   alkaline diuresis     
b. Renal replacement therapies for ARF 
 
• Hemodialysis till recovery 
• Peritoneal dialysis 
c. Conservative Management of CKD  
 
• Fluid restriction to < 1 L/d 
• Salt restriction 1-2 g/d 
• Protein 0.6 g/kg/d of high biologic value 
• Potassium free diet 
• Calories 35 Kcal/kg/d 
• Antihypertensives 
• Tight glycemic control 
• Iron, calcium and vitamin supplements 
d. Renal replacement therapies for CKD 
 
• Hemodialysis 
• Peritoneal dialysis 
• Renal transplant 
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RESULTS 
 
153 Patients were taken up for the study.  
• Total number of Patients:  153 
• Number of ARF:    71 (46%) 
• Number of CKD:    82 (54%) 
• Number of Males:    102 (67%) 
• Number of Females:   51 (33%) 
 
The Sex distribution is shown in TABLE 1. 
 
                                                           TABLE 1 
 
                            SEX DISTRIBUTION OF RENAL FAILURE 
 
 
DIAGNOSIS 
 
MALE 
 
FEMALE 
TOTAL 
NUMBER 
(n-153) 
 
ARF 
 
54 17 71 (46%) 
CKD 48 34 
 
82 (54%) 
 
 
TOTAL 
 
102 (67%) 51 (33%) 153 
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ARF 
 
 
TABLE 2 
 
                               AGE AND SEX DISTRIBUTION IN ARF 
 
AGE 
(YEARS) 
MALE FEMALE TOTAL 
(n-71) 
13-20 
 
2 
 
1 
 
3 (4%) 
 
21-30 
 
6 
 
- 
 
6 (8%) 
 
31-40 
 
8 
 
1 
 
9 (13%) 
 
41-50 
 
8 
 
6 
 
14 (20%) 
 
51-60 
 
11 
 
5 
 
16 (23%) 
 
>60 
 
19 
 
4 
 
23 (32%) 
 
 
TOTAL 
 
54 (76%) 
 
17 (24%) 
 
71 
 
 
• Mean Age: 52.5 YEARS 
• Range: 14-88 
 
75% of the patients were above the age of 41 years. 76% were males and  
24% were females. 
 
 
 35 
TABLE 3 
 
ETIOLOGY OF ARF 
 
 
S.NO. 
 
ETIOLOGY 
TOTAL 
(n-71) 
 
1 
 
ACUTE DIARRHEAL DISEASE 
 
11 (16%) 
 
2. 
 
MALARIA 
 
8 (11%) 
 
3. 
 
LEPTOSPIROSIS 
 
8 (11%) 
 
4. 
 
CONGESTIVE CARDIAC FAILURE 
 
8 (11%) 
 
5. 
 
DRUGS 
 
6 (8%) 
 
6. 
 
SEPSIS 
 
6 (8%) 
 
7. 
 
GASTROINTESTINAL BLEEDING 
 
3 (4%) 
 
8. 
 
ACUTE GLOMERULONEPHRITIS 
 
3 (4%) 
 
9. 
 
DIABETIC KETOACIDOSIS 
 
2 (3%) 
 
10. 
 
OBSTRUCTIVE UROPATHY 
 
2 (3%) 
 
11. 
 
ACUTE  PYELONEPHRITIS 
 
2 (3%) 
 
12. 
 
RHABDOMYOLYSIS 
 
1 (1.4%) 
 
13. 
 
ACUTE PANCREATITIS 
 
1 (1.4%) 
 
14. 
 
UNCLASSIFIED 
 
10 (14%) 
 
 
The most common cause of ARF is Acute diarrheal disease. Infective diseases 
contributed to 50% of the ARF. 
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TABLE 4 
CLINICAL FEATURES OFARF 
 
S. NO SYMPTOMS TOTAL 
(n-71) 
1.  FEVER 44 (62%) 
2.  VOMITING 33 (46%) 
3.  GIDDINESS 24 (34%) 
4.  DYSPNEA 22 (31%) 
5.  OLIGURIA 20 (28%) 
6.  MYALGIA 17 (24%) 
7.  DIARRHEA 16 (22%) 
8.  PEDAL EDEMA 16 (22%) 
9.  ALTERED SENSORIUM 14 (20%) 
10.  HEADACHE 11 (15%) 
11.  FACIAL PUFFINESS 8 (11%) 
12.  DYSURIA 8 (11%) 
13.  SEIZURES 5 (7%) 
14.  HEMATURIA 4 (6%) 
 
TABLE 5 
 
 
S.NO. 
 
SIGNS 
TOTAL 
(n-71) 
1 ANEMIA 24 (34%) 
2. CRACKLES 14 (20%) 
3. RAISED JVP 12 (17%) 
4. ASCITES 7 (10%) 
5. HEMIPLEGIA 6 (8%) 
6. JAUNDICE 6 (8%) 
 
Fever was the most commonest symptom and anemia was the most commonest sign. 
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TABLE 6 shows the causes of fever in the patients with ARF. 
 
 
TABLE 6 
 
ARF WITH FEVER 
 
 
S.NO. 
 
ETIOLOGY 
 
TOTAL 
(n-44) 
1 ACUTE DIARRHEAL DISEASE 9 (20%) 
2. MALARIA 8 (18%) 
3. LEPTOSPIROSIS 8 (18%) 
4. SEPSIS 5 (11%) 
5. ACUTE PYELONEPHRITIS 2 (5%) 
6. PYOPNEUMOTHORAX 1 (2%) 
7. PUO 11 (25%) 
 
PUO were the most common cause of fever followed by ADD, Malaria and 
Leptospirosis. 
 
 
 
  
TABLE 7  
CLINICAL PROFILE OF THE COMMON CAUSES OF ARF 
 
 
 
 
  
CLINICAL PROFILE 
 
ADD 
(n-11) 
MALARIA 
(n-8) 
LEPTOSPIROSIS 
(n-8) 
CCF 
(n-8) 
DRUGS 
(n-6) 
SEPSIS 
(n-6) 
MALE 8 6 5 6 5 4 
FEMALE 3 2 3 2 1 2 
MEAN AGE 50 44 48 62 52 58 
AGE RANGE 19-70 14-65 14-70 42-80 41-88 46-70 
FEVER 9 8 8  2 5 
MYALGIA  5 4    
DIARRHEA 11  3    
VOMITING 8 5 5    
HEADACHE  4 3    
DYSPNEA  3  6  2 
OLIGURIA 5 5  3 3 4 
ANEMIA  6 3   3 
MEAN BLOOD UREA 71 92 75 75 74 78 
MEAN S. Cr 2.4 4.2 2.6 2 3.5 3.3 
RANGE OF S. Cr 1.8-4.8 1.7-17.1 1.5-4.0 1.6-3.1 1.9-7 1.8-5.4 
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TABLE 8 
 
BLOOD PRESSURE IN ARF 
 
BLOOD PRESSURE (mm Hg) NUMBER (n-71) 
<90/60 9 (13%) 
 
PREHYPERTENSION 
120-139/80-89 
 
3 (4%) 
STAGE I HYPERTENSION 
140-159/90-99 
 
7 (10%) 
STAGE 2 HYPERTENSION 
>160/100 
 
 
15 (21%) 
            
• Mean: 125/80 mm Hg 
• Range: 60-210/40-130 mm Hg 
 
13% of the people had hypotension BP < 90/60 mm Hg 
             
 
 
 
TABLE 9 
 
ANEMIA IN ARF 
 
HEMOGLOBIN (g%) NUMBER (n-71) 
10-8 28 (40%) 
8-5 11 (15%) 
<5 - 
                                 
• Mean: 8.5 g% 
• Range: 6-10 g% 
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TABLE 10 
 
BLOOD UREA IN ARF 
 
BLOOD UREA NUMBER (n-71) 
40-59 29 (41%) 
60-79 11 (4%) 
80-89 11 (4%) 
>100 16 (23%) 
              
• Mean: 79 mg% 
• Range: 4-288 mg% 
         
 
TABLE 11 
 
SERUM CREATININE IN ARF 
 
SERUM CREATININE NUMBER (n-71) 
1.5-2.9 53 (75%) 
3.0-4.9 12 (17%) 
>5 6 (8%) 
 
• Mean: 2.7 mg% 
• Range: 1.5- 17.1 mg% 
 
75% of patients with ARF had S. Creatinine < 3.0 mg% which 
shows that majority had mild renal failure. 
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TABLE 12 
 
SERUM SODIUM IN ARF 
 
SERUM SODIUM NUMBER (n-71) 
<135 24 (34%) 
135-145 40 (56%) 
>145 7 (10%) 
     
• Mean: 137 mEq/L 
• Range: 118-152 mEq/L 
 
                                       34% of patients had hyponatremia. 
 
 
TABLE 13 
 
SERUM POTASSIUM IN ARF 
 
 
SERUM POTASSIUM 
 
NUMBER (n-71) 
<3.5 13 (18%) 
3.5-5 51 (72%) 
>5 7 (10%) 
   
• Mean: 4.1 mEq/L 
• Range: 2.3-5.8 mEq/L 
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TABLE 14 
 
URINE ALBUMIN IN ARF 
 
URINE ALBUMIN NUMBER (n-71) 
Trace 17 (24%) 
+ 9 (12%) 
++ 4 (5%) 
+++ 4 (5%) 
++++ 1 (1%) 
 
Significant proteinuria is present in 11% of patients. 
 
 
TABLE 15 
 
RENAL REPLACEMENT THERAPIES IN ARF 
 
 
RENAL REPLACEMENT THERAPY 
 
NUMBER 
(n-71) 
PD 1(1%) 
HD 2(3%) 
 
• Mortality: 2 (3%).  
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CHRONIC KIDNEY DISEASE 
Number of CKD: 82  
 
TABLE 16 shows the age and sex distribution in CKD 
 
 
 
TABLE 16 
 
AGE AND SEX DISTRIBUTION IN CKD 
 
 
 
AGE 
(YEARS) 
MALE 
 
FEMALE 
 
TOTAL 
(n-82) 
 
13-20 - 2 2 (2%) 
21-30 1 1 2 (2%) 
31-40 8 5 13 (16%) 
41-50 13 4 17 (21%) 
51-60 10 7 17 (21%) 
>60 16 15 31 (38%) 
TOTAL 48 (59%) 34   (41%) 82 
 
• Mean Age: 55 years          
• Range: 13-82 years 
 
80% of the patients were above the age 40 years 
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TABLE 17 
 
ETIOLOGY OF CKD 
 
S. NO. ETIOLOGY NUMBER 
(n-82) 
1. CHRONIC GLOMERULNEPHRITIS (CGN) 40 (49%) 
2. DIABETIC NEPHROPATHY (DN) 37 (45%) 
3. OBSTRUCTIVE UROPATHY 6 (7%) 
 
CGN was the most commonest cause of CKD which was closely 
followed by Diabetic Nephropathy. 
TABLE –18 shows the comparative age and sex distribution between the two 
most common causes of CKD – CGN and DN.                                                
TABLE 18 
 
AGE AND SEX DISTRIBUTION OF CKD and DN 
 
CGN (n-40) DN (n-37) AGE 
(YEARS) MALE FEMALE TOTAL MALE FEMALE TOTAL 
13-20 - 2 2 - - - 
   21-30 1 1 2 - - - 
31-40 5 2 7 3 3 6 
41-50 9 1 10 3 3 6 
51-60 2 1 3 5 6 11 
>60 12 4 16 3 11 14 
TOTAL 29 (73%) 11 (27%) 40 14 (38%) 23 (62%) 37 
MEAN 48 56 
RANGE 13-82 34-78 
 
In CGN, the Mean age was 48, while in DN it was 56 years. In CGN 
there was male preponderance (73%), but in DN females (62%) were 
more.  
                                      45  
CLINICAL FEATURES OF CKD 
TABLE 19 
 
S. NO. SYMPTOMS NUMBER (n-82) 
1 PEDAL EDEMA 57 (70%) 
2. OLIGURIA 44 (54%) 
3. DYSPNEA 40 (49%) 
4. FACIAL PUFFINESS 34 (49%) 
5. GIDDINESS 29 (35%) 
6. VOMITING 24 (29%) 
7. CHEST PAIN 14 (17%) 
8. DYSURIA 8 (10%) 
9. HICCUPS 5 (6%) 
10. HEMATURIA 2 (2%) 
 
 
TABLE 20  
 
S. NO. SIGNS NUMBER (n-82) 
1 ANEMIA 47 (57%) 
2. CRACKLES 25 (30%) 
3. ASCITES 17 (21%) 
4. RAISED JVP 15 (18%) 
4. ANASARCA 12 (15%) 
5. HEMIPLEGIA 6 (8%) 
 
Leg swelling was the most common symptom and anemia was 
the most common sign. 
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TABLE 21 and 22 show the past history of DM, DN, SHT,CAD, CKD in all 
the patients with CGN and DN. 
TABLE 21 
 
PAST HISTORY IN CGN 
 
CGN (n-40)     
NO. OF YEARS SHT CAD CKD 
<1 5 - 5 
1-5 7 4 4 
>5 5 - 2 
TOTAL 17 (43%) 4 (10%) 11 (28%) 
 
• SHT: Systemic Hrpertension    
• CAD: Coronary artery Disease 
• DN: Diabetic Nephropathy 
 
Past history of Systemic hypertension was present in 43% of 
patients with CGN. 28% of patients with CGN were known 
patients of CKD. 
TABLE 22 
 
PAST HISTORY IN DN 
 
DN (n-37)  
NO. OF YEARS DM DN SHT CAD CKD 
<1 1 4 4 1 2 
1-5 13 11 10 2 2 
>5 14 1 6 - 1 
          Total 28 (76%) 16 (43%) 20 (54%) 3 (8%) 5 (14%) 
 
76% of patients with DN were known cases of DM. 54% of patients with 
DN had past history of SHT. 
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TABLE 23 
 
BLOOD PRESSURE IN CKD 
 
BLOOD PRESSURE (mm Hg) NUMBER (n-82) 
 
PREHYPERTENSION 
120-139/ 80-89  
 
5 (6%) 
STAGE 1 HYPERTENSION 
140-159/ 90-99 
 
17 (21%) 
STAGE 2 HYPERTENSION >160/ 100 42 (51%) 
ACCELERATED HYPERTENSION >210/130 11 (13%) 
 
• MEAN BP: 152/92 mm Hg 
• RANGE: Systolic 90-220/ Diastolic 60-170 mm Hg 
 
72% of CKD patients were hypertensive. Most of them had Stage 2 
hypertension (≥160/100 mm Hg) which shows that control of 
hypertension is poor. 
 
TABLE 24 
 
ANEMIA IN CKD 
 
HEMOGLOBIN (g%) NUMBER (n-82) 
 
                 10-8 24 (29%) 
8-5 26 (32%) 
<5 1 (1%) 
 
• MEAN HEMOGLOBIN – 8.1 g% 
• RANGE- 4-10 g% 
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TABLE 25 
 
BLOOD UREA IN CKD 
 
BLOOD UREA (mg%) NUMBER (n-82) 
40-59 13 (16%) 
60-79 26 (32%) 
80-89 14 (17%) 
>100 29 (32%) 
 
• MEAN- 87 mg% 
• RANGE- 40-231 mg%  
 
 
 
             TABLE 26  
 
             SERUM CREATININE IN CKD 
 
 
SERUM CREATININE (mg%) 
 
NUMBER (n-82) 
1.5-2.9 45 (55%) 
3.0-4.9 18 (22%) 
>5 19 (23%) 
 
• MEAN- 3.7 mg% 
• RANGE- 1.5-13.2 mg% 
 
           23% of patients had severe renal failure with S.Creatinine of   >5.0mg% 
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TABLE 27 
 
SERUM SODIUM IN CKD 
 
SERUM SODIUM (mEq/L) 
 
Number (n-82) 
<135 20 (24%) 
135-145 47 (57%) 
>145 15 (18%) 
 
• MEAN- 139 mEq/L 
• RANGE- 114-152 mEq/L 
 
 
 
 
TABLE 28 
 
                                                  SERUM POTASSIUM IN CKD 
 
SERUM POTASSIUM (mEq/L) NUMBER (n-82) 
<3.5 15 (18%) 
3.5-5 57 (70%) 
>5 10 (12%) 
 
• MEAN: 3.9 mEq/L  
• RANGE: 2.2-6.7 mEq/L 
 
                                      12% of patients with CKD had hyperkalemia. 
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TABLE 29 compares the proteinuria between CGN and DN.                                                    
 
 
                                                             TABLE 29  
 
                                                  URINE ALBUMIN IN CKD 
 
 
URINE ALBUMIN 
 
CGN(n-40) 
 
DN(n-37) 
 
TOTAL(n-82) 
Trace 9(22%)    7(19%) 16(20%) 
+ 8(20%) 12(32%) 20(24%) 
++ 8(20%) 12(32%) 20(24%) 
+++ 1 (3%) 3 (8%) 4 (5%) 
++++ 1 (3%) 1 (3%) 2 (2%) 
 
Significant proteinuria occurred in 26% of patients with CGN and 
43% of                                                                                                      
patients with DN. 
                                                               TABLE 30  
 
ECG IN CKD 
 
 
ECG 
 
NUMBER (n-82) 
LVH 31 (38%) 
CAD/ISCHEMIA 13 (16%) 
SINUS TACHYCARDIA 5 (6%) 
TALL T WAVES 5 (6%) 
 
 
                    38% of patients had evidence left ventricular hypertrophy in ECG. 
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TABLE 31 
 
CHEST X-RAY IN CKD 
 
 
CHEST X-RAY 
 
NUMBER(n-82) 
CARDIOMEGALY 43 (53%) 
PLEURAL EFFUSION 12 (15%) 
PULMONARY EDEMA 6 (7%) 
 
 
53% of patients with CKD had cardiomegaly in Chest X-Ray. These    
.           patients also had ECG evidence of LVH 
 
                                                             TABLE 32  
 
                                                    USG KIDNEYS IN CKD 
 
Size (cm) Number (n-82) 
9-8 15 (18%) 
8-7 33 (40%) 
<7 11 (13%) 
 
                             40% of patients had kidney size in the range of 8-7 cm. 
 
 
 
TABLE 33 
 
          RENAL REPLACEMENT THERAPIES 
 
 
Renal Replacement Therapy 
 
Number(n-82) 
PD 5 (6%) 
HD 6 (7%) 
          
• MORTALITY: 1(1%) 
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DISCUSSION 
Kidney diseases are increasing day by day. It is important that these 
diseases are recognised early and referred at the appropriate time. Renal failure 
can be ARF or CKD. The incidence of ARF is around 1% of all the patients 
admitted to the general hospitals14. The prevalence of CKD in India is 5 to 10 per 
one lakh of the population. The increasing prevalence of chronic kidney diseases 
(CKD) has now been recognised as a major public health problem globally. Of the 
one lakh ESRD patients emerging every year, only 9,000 are put on dialysis. Out 
of this, 60 per cent drop out and 20 per cent die due to inadequate dialysis.  
In this study renal failure was diagnosed utilising S.creatinine ≥1.5 mg/dl 
as the criteria. It is difficult to diagnose ARF or CKD at the first evaluation. As 
ARF is a reversible renal disease and CKD is an irreversible renal disease, it is 
absolutely essential not to make an error in diagnosis. The diagnosis of ARF or 
CKD was arrived only after further evaluation and observation for reduction in 
S.creatinine. In addition, acute on chronic ARF can make diagnosis difficult. In 
this study, all patients were labelled as renal failure as diagnosis and further 
classified as ARF or CKD only after evaluation. 
Our Study screened 153 patients with S.Creatinine ≥1.5 mg/dL. Of these, 
71 (46%) patients had ARF and 82 (54%) patients had CKD. Of these 102 (67%) 
were males and 51(33%) were females. The mean age was 53 years. 
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ACUTE RENAL FAILURE 
 
71 patients had ARF. The Age distribution for ARF varied from 14-88. 
The Mean Age was 52.5 years. Out of 71 patients, 54 (76%) were males and 
17 (24%) were females. 
 
ETIOLOGY 
 
The most common cause of ARF was found to be acute diarrheal 
disease (16%). The other causes are malaria (11%), leptospirosis (11%), 
congestive cardiac failure (11%), drug induced ARF (8%), sepsis (8%), 
gastrointestinal bleeding(4%), Acute glomerulonephritis (4%), diabetic 
ketoacidosis (3%), obstructive uropathy (3%), acute pyelonephritis(3%). The 
other rare causes were rhabdomyolysis(1%), acute pancreatitis(1%). For 14% 
of patients the etiology was not surely defined and they were categorized as 
unclassified. Among the unclassified, most had pyrexia of unknown origin 
which might be malaria or Leptospirosis, but the investigations were negative. 
Infections contributed to around 50% of the ARF.  Our study did not invlove 
the obstetric and surgical causes of ARF because we have included only the 
patients in the medical wards. The 2 patients with obstructive uropathy were 
admitted in the medical ward as renal failure and subsequently the etiology 
was defined by the means of investigations. 
M. Jayakumar et al showed in a study done in chennai during 1995-2004, 
published in 2006 that the medical causes contributed to 88% of the ARF  
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followed by obstetric causes (9%) and surgical causes (3%). Among the 
medical causes acute diarrheal disease (28%) remained the common cause of 
ARF,  followed  by  drugs (13%),  glomerulonephritis (9%),  sepsis (9%), 
snake bite (8%), leptospirosis (8%), malaria (4%), Copper Sulphate (4%). Our 
study did not  include  the  patients in the intensive medical care unit and 
therefore data of snake bite and Copper Sulphate poisoning who get admitted 
directly in the IMCU, were not there in our study14. 
RP Mathur and A Bhargav showed that in a study done in 2003-2004, 
the predominant etiological factors were septicemia (22%), alcoholic liver 
disease (19%), acute gastroenteritis (15%), falciparum malaria (8%), cardiac 
failure (7%), cirrhosis (7%), pneumonia (5%), stroke (5%) and others (13%) 
Others includued causes like benign prostatic hypertrophy with obstructive 
uropathy, post operative ARF, leptospirosis and trauma26. 
Sharma VK and Dubey TN reported that hypovolemia is the commonest 
cause of ARF. The etiological causes in their study were acute gastroenteritis 
with hypovolemia 28%, falciparum malaria 23%, obstrutive uropathy 13%, 
pregnancy related 8%, septicemia 8%, hepatorenal 5%, snake bite 4%, AGN 
3%,  NSAID induced 3% and miscellaneous  5%27. 
CLINICAL FEATURES OF ARF 
The most common symptoms in our study were fever 62%, vomiting 
46%, giddiness 34%, dyspnea 31%, oliguria 28%, pedal edema 22%. The other 
symptoms diarrhea 22%, altered sensorium 20%, headache 15%, dysuria 11%,  
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hematuria, seizures. Fever being the most commonest symptom implicates that 
infective diseases were the commonest cause of ARF. 
RP Mathur and A Bhargav reported that the most common presenting 
symptoms were fever 46%, vomiting 35%, jaundice 27%, diarrhea 21%, 
breathlessness 20%, hematemesis 12%. oliguria 36% and anuria 6%26. 
Fever was present in  44 (62%) of patients. Of these, 20% had diarrheal 
disease with fever, 18% had malaria, 18% had leptospirosis, 11% had sepsis, 5% 
had pyelonephritis. 25% had pyrexia of unknown origin (PUO) because the 
investigations were negative. PUO might most probably be malaria or 
leptospirosis because the QBC for malarial parasites is only 40% sensitive and 
MSAT (Macroscopic Slide Agglutination Test)  becomes positive only the end of 
the first week of fever.  
Vomiting occurred in 33 (46%) patients. Vomiting further complicated the 
malarial and leptospiral ARF by causing pre renal element. Giddiness and 
breathlessness occurred in 34% and 31% of patients respectively. Giddiness 
represented the hemodynamic compromise. Oliguria occurred in only 28% of the 
patients. The others did not complain of decreased urine output. Altered 
sensorium was present in 20% of patients, which was due to cerebral malaria, 
uremic encephalopathy and sepsis. 
The most common sign was anemia, which was present in 34% of the 
patients. Most of these patients had malaria and gastrointestinal bleeding. The 
other signs are lung crackles 20%, elevated JVP 17%, ascites 10%, jaundice 8%. 
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The crackles were due to pulmonary edema and consolidation. Jaundice 
occurred in the patients with malaria and leptospirosis.   
ACUTE DIARRHEAL DISEASE 
Acute diarrheal disease was present in 11(16%) patients. The mean age 
of these patients was 50 years. All patients had diarrhea. 8 (73%) of patients 
had associated vomiting. 9 patients (82%) had fever. 5(45%) patients were 
dehydrated, hypotensive and oliguric. The mean B.urea was 71 mg% with the 
mean S.creatinine of 2.4 mg%. One patient had uremic symptoms and died. 
MALARIA 
8 (11%) patients had malarial fever. The mean age was 44 years. All 
had fever. Out of these, 5 (63%) patients had oliguria, headache, vomiting and 
were anemic. 4 (50%) patients had cerebral malaria and one patient had 
jaundice. The mean B. urea was 92 mg% with  a  mean   S.creatinine of 4.2 
mg%.  One (13%) patient had P. falciparum infection and 7 (87%) patients had 
P. vivax infection. All were treated with quinine. One (13%) patient was 
started on hemodialysis as he had severe renal failure (S.creatinine-17.1 mg%) 
with uremic symptoms. The incidence of ARF in malaria varies from 1-60%.  
M. Jayakumar et al shows that malarial ARF constitued to 4% of ARF, 
which was mostly due to falciparum14. RP Mathur and A Bhargav showed that 
falciparum caused  8% of ARF in their study26. 
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LEPTOSPIROSIS 
 
8 (11%) patients had leptospirosis. The mean age was 48. All the 
patients had fever. 5 (63%) patients had vomiting. 4 (50%) patients had severe 
myalgia. 3 (38%) patients had headache, diarrhea and were anemic and 
jaundiced. The mean B. urea was 75 mg% with the mean S.creatinine of 2.6 
mg%. MSAT was ++ in 3 patients and +++ in 5 patients. MAT was positive in 
two patients and the serogroups were semoranga and australis. Semoranga is a 
non pathogenic strain. 
Muthusethupathi et al showed in his study in 1991 that renal failure 
complicates leptospiral fever in 71% of patients and it was severe renal failure 
in 21% of patients9. Recent study (2005) shows renal failure in leptospirosis 
has decreased to 10%. M. Jayakumar et al study showed leptospirosis 
constituted 8% of ARF. They also showed a decline in leptospiral ARF from 
31% in 1991 to 8% in 200414. All our  patients were treated with intravenous 
Crystalline Penicillin  and C.Doxycycline. 
CARDIAC FAILURE 
8 (11%) patients with ARF had congestive cardiac failure. 2 patients had 
Rheumatic heard disease with atrial fibrillation and cardiac failure. The other 
six patients had Coronary artery disease with congestive cardiac failure. The 
mean age was 62 years. All patients had breathlessness. 7 (88%) patients had 
volume overload in the form of either pedal edema, facial puffiness, ascites  
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and raised JVP. 4 (50%) patients presented with pulmonary edema. The mean   
B. urea was 75 mg% with the mean S.creatinine of 2.0 mg%. 
SEPSIS 
 
Sepsis with ARF was found in 6 (8%) patients. The mean age was 58 
years. 5 patients had fever. 4 patients were oliguric. 2 patients had altered 
sensorium. 3 patients had pneumonia, 2 patients had cellulitis, 1 patient had 
gluteal abscess. The mean B. urea was 78 mg% with the mean S.creatinine of 
3.3 mg%. Sepsis contributed 9% of ARF in the study of  Jayakumar M et al14. 
DRUGS 
Drugs caused ARF in 6 (8%) patients. The mean age was 52 years. 4 
patients had NSAID intake, one patient had aminoglycoside injectons and the 
other patient took native medicine for low back ache.  The mean B. urea was 
74 mg% with the mean S.creatinine of 3.5 mg%. The patient with native 
medicine induced ARF had uremic symptoms with S. creatinine of 7 mg% and 
was started on hemodialysis. Drugs caused 13% of ARF in the study of 
Jayakumar M et al. The common drugs were unknown analgesics, rifampin 
and NSAIDS14,28. 
Gastrointestinal bleeding was present in 3 patients. 2 patients had 
hemetemesis and one patient had malena. All were hypotensive. 
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3 patients had acute glomrulonephritis. All of these patients had facial 
puffiness, pedal edema, oliguria and hypertension. Two patients had hematuria 
and proteinuria. Glomerular disease oincluding crescentric glomerulonephritis, 
postinfective proliferative glomerulonephritis, SLE and IgA nephropathy 
accounted for 9% of ARF in Jayakumar M et al study14. 
Diabetic ketoacidosis occurred in 2 patients. One patient had Type 1 
DM and the other had Type 2 DM. Both of these patients had severe vomiting. 
Their creatinine returned to <1.5 mg% on the third day. 
2 patients had obstructive uropathy. One patient had Ca Bladder and 
was operated. The other patient had bilateral ureteric stones and was surgically 
managed. 
One patient had alcohol induced rhabdomyolysis with myoglobinuria 
with positive benzidine test. He was started on forced alkaline diuresis. 
Rhabdomyolysis accounted for 0.6% of ARF in Jayakumar M et al study14. 
 
BLOOD PRESSURE 
4% of patients had prehypertension. Stage I hypertension was present in 
10% of patients. 15 (21%) patients had stage 2 hypertension. Of these 8 had 
systemic hypertension and 2 patients had AGN. The mean systolic B.P was 
125 mm Hg. 9 (13%) patients had B.P <90/60 mm Hg. Of these, 5 patients had 
diarrhea and 3 had vomiting. One patient had CCF and  one patient had 
hemetemesis.  
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ANEMIA 
Anemia with hemoglobin <10 g% was found in 55% of patients. Of 
these, 15% had  Hb <8 g%. These patients had malaria, leptospirosis and 
gastrointestinal bleeding.  The mean Hb was 8.5 g%. 
INVESTIGATIONS IN ARF 
 
 
The mean B. urea was 79 mg%. 29 (41%) patients had B. urea  in the  
range of 40-59. 16 (23%) patients had B. urea> 100 mg%. 10 (63%) of these 
patients had infections like malaria, leptospirosis, sepsis, diarrheal disease and 
PUO. 
 
The mean S.Creatinine was 2.7 mg%. 53 (75%) patients had mild renal 
failure with creatinine <3mg%. 6 (8%)   patients had severe renal  failure with   
creatinine > 5 mg%. In the patients with severe renal failure, infective etiology 
was present in 4 patients, out of which 2 had PUO, one had malaria and one 
had sepsis. 2 patients had drug induced ARF and severe renal failure. Two 
patients were started on hemodialysis and one patient was put on peritoneal 
dialysis because of hemodynamic unstability. The patient who was put on 
peritoneal dialysis died. 
The mean S. sodium was 137 mEq/L. 34% of patients had hyponatremia 
(S.Sodium < 135 mEq/L). 10% of patients had hypernatremia (S.Sodium >145 
mEq/L). Hyponatemia was found common in ARF.The mean S.potassium was  
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4.1 mEq/L. 7 (10%) of patients had hyperkalemia (S.Potassim > 5.0 mEq/L).  
Of these 3 patients had leptospirosis, one had malaria, one had diarrheal 
disease, one had AGN and one patient had pyelonephritis. 
Significant proteinuria was present in 9 (11%) of patients. 17(24%) 
patients had trace albumin which included patients with Type 2 DM, urinary 
tract infection, leptospirosis and malaria. 9 (12%) patients including type 2 
DM and malaria had + urine albumin. 4 (5%)  patients with PUO had ++ urine 
albumin.  4 (5%)  patients with AGN and PUO  had +++ urine albumin.   
 
9 (12%) patients had ischemic changes in the ECG and they were 
known CAD patients. 11 (15%) patients had cardiomegaly in the Chest X-Ray. 
6 (9%) had pleural effusion.  6 (9%) had pulmonary edema in the Chest X-
Ray.   
TREATMENT 
The patients with ADD were treated with intravenous ciproflxacin, iv 
metrogyl and Intravenous fluids. Normal saline was used as a replacement 
fluid for vomiting. Ringer lactate solution was used for diarrhea.  
Patients with malaria were given iv quinine. Patients with leptospirosis 
were treated iv crystalline penicillin and C. Doxycycline. Patients with sepsis 
were given high grade antibiotics and other supportive measures.  
AGN was treated with salt restriction to < 2 g/d, fluid restriction to < 
1L/d, Calories 35-50 kcal/kg/d mainly by carbohydrates, restriction of 
potassium intake, antihypertensives and diuretics.  
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Acute pyelonephritis was treated with sensitive antibiotics. DKA was 
treated with adequate fluids, antibiotics and Insulin. The offending nephrotoxic 
drugs were withdrawn. Forced alkaline diuresis was given for myoglobinuria. 
RENAL REPLACEMENT THERAPY 
Two patients were started on hemodialysis and one patient was started 
on peritoneal dialysis. All had severe hyperkalemia and S.creatinine >5mg% 
and uremia.  Patients who were started on HD included malarial ARF and 
native medicine induced ARF. A patient with PUO was started on PD and he 
died. 
MORTALITY 
The mortality rate was 3%. It was low because most of the patients 
hadmild renal failure which was conservatively managed.  
 
CHRONIC KIDNEY DISEASE 
In our study, 82 (54%) patients had CKD. Of these 48 (59%) were 
males and 34 (41%) were females. The mean age was 55 years and range was 
13-82 years. 80% of patients were above the age of 40 years. 
ETIOLOGY 
 
The most common cause of CKD was found to be Chronic 
glomerulonephritis 49%. 37 (45%) patients had Diabetic Nephropathy. 6 (7%) 
had obstructive uropathy.  CGN also included the chronic interstitial nephritis 
since we dont have evidence to differentiate both of them. 
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Vikrant S and Kaushal SS reported in their study that the causes of CKD 
were - Diabetic nephropathy 64 (28.4%), Hypertension 40 (17.8%), CGN 20 
(8.9%), CIN 95 (42.2%), ADPKD 5 (2.2%), and other 1 (0.4%)29.  Dharan KS, 
John GT determined the etiological profile of chronic kidney disease (CKD) 
by analyzing the renal biopsies of patients with severe CKD. 70% of these 
patients had glomerulonephritis as the histological diagnosis. 12% had 
interstitial nephritis, 7% had hypertensive arteriosclerosis and 6% had 
metabolic nephropathies. This shows that the predominant cause of CKD is 
glomerular disease30. 
Acute on chronic CKD was present in five patients. Of these three  had  
CGN  and two patients had DN. Two patients had diarrheal disease, two patients  
had CCF with pulmonary edema. 
The age and sex distribution showed that the mean age for CGN was 48 
years and DN was 56 years. In CGN, 73% were males and 27% were females. 
In DN, majority were females (62%) and males were 38%. There were no 
patients with DN below the age of 34. 
 
CLINICAL FEATURES OF CKD 
 
Pedal edema was the commonest symptom which was present in 70% of the 
patients. Oliguria occurred in 54% of patients. The other symptoms were 
breathlessness 49%, facial puffiness 41%, giddiness 35%, vomiting, chest pain, 
dysuria, hiccups and hematuria. 
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Anemia was the most commonest sign which was seen in 57% of the 
patients..Lung crepititions was present in 30%. Ascites occurred in 21%.  
43% of patients with CGN were known cases of SHT.  28% of patients were 
known CKD patients. The rest 72% were diagnosed at this present admission.  
76% of the DN patients had history of DM and 35% had history of DM in the 
range of  1-5 years. 24% of the patients were diagnosed with DN with CKD at 
this present admission. Out of 82 patients with CKD,  37 (45%) had history of 
SHT. 
Hypertension is an important risk factor for adverse cardiovascular 
outcome in patients with CKD31. In our study, 72% of CKD patients were 
hypertensive. 51% of the patients had Stage 2 hypertension (>160/100 mm Hg) 
which shows that control of hypertension is poor. 13% of patients had 
accelerated hypertension >210/130 mm Hg. Most of these patients had acute 
left ventricular failure. The mean BP was 152/92 mm Hg. Kumar V and 
Kaushal SS reported that 60% of patients with CKD were hypertensive32. 
 
INVESTIGATIONS 
 
61%  of  the  patients with CKD were anemic with Hemoglobin level< 
10 g%.  The mean Hb was 8.1 g%. The Hb level varied from 4-10 g%.    
The mean B. Urea in the patients with CKD was 87 mg%. 35% of the patients 
had urea >100 mg%. The mean S.creatinine was 3.7 mg%. 23% of the patients 
had severe renal failure with S. creatinine >5 mg%.  
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The mean S. sodium  was 139 mEq/L. 24% of the patients were 
hyponatremic and 18% were hypernatremic. The mean S. potassium was 3.9 
mEq/L. 12% of the  patients were hyperkalemic. Most of them with 
hyperkalemia had severe renal failure with S.creatinine of >5 mg% and uremic 
symptoms. Significant proteinuria occurred in 26% of patients with CGN and 
43% of patients with DN. Kumar V and Kaushal SS reported that 80% of 
patients with CKD had proteinuria of varying degrees32. 
 
Cardiovascular disease is the leading cause of morbidity and mortality in 
patients with CKD. 38% of the patients had ECG evidence of left ventricular 
hypertrophy. 16% of the patients had evidence of coronary artery disesase and 
ischemia. 6% of the patients had tall T waves and hyperkalemia. 53% of the 
patients had cardiomegaly in the X-Ray. 15% had pleural effusion and  5%  
had pulmonary edema. Kumar V and Kaushal SS showed 57% of patients with 
CKD had evidence of left ventricular hypertrophy and coronary artery disease 
in ECG32. 
 
71% of the patients had kidney size < 9 cm. 40% of patients had kidney 
size in the range of 8-7 cm. 7% of the patients had hydroureteronephrosis. 22% 
of the patients had normal sized kidneys. 
 
                                                                                                                            
 66 
 
TREATMENT 
 
5 out of the 82 CKD patients were taken up for the transplantation 
program because they had suitable donors and further evaluation was started. 
 
Protein restriction of 0.6-0.8 g/kg/d of high biologic value protein was 
advised for the patients. No added salt diet and fluid restriction to output plus 
500ml was suggested. Hypertension was aggressively treated with loop 
diuretics and calcium channel blockers. Potassium restriction was done. 
Anemia was treated with iron tablets because most of the patients had 
inadequate iron stores. Hemodialysis was started for 6 patients. 5 patients were 
put on peritoneal dialysis because they had cardiac complications like dilated 
cardiomyopathy. 
 
The mortality was 1%. 
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                                                   SUMMARY 
• 153 patients with S.Creatinine >1.5 mg% were analysed in our study. 
71(46%) had ARF and 82 (54%) had CKD. 
• The most common etiology of ARF was acute diarrheal diseases(16%), 
followed by malaria, leptospirosis, CCF, sepsis, drugs and AGN. 
Infective diseases contributed to > 50% of the ARF. 
• The most common symptom of ARF was fever (62%), followed by 
vomiting, giddiness and breathlessness. Oliguria occurred only in 28% 
of the patients. The most common sign was anemia (34%).  Jaundice 
occurred in 8% of the patients.  
• Of all the common causes of ARF, malaria caused severe renal failure 
with mean S.creatinine of 4.2 mg%, followed by drugs and sepsis. Most 
of the patients with CCF were dyspneic. Anemia occurred  commonly 
in malaria. Oliguria occurred commonly in  ADD and malaria. 
• 13% of patients with ARF had hypotension. 55% of the patients were 
anemic. The mean B. urea was 79 mg% and the mean S.creatinine was 
2.7 mg%. 34% of patients had hyponatremia and 10% had hyperkalemia 
and 11% had significant proteinuria. 
• 1 patient  had peritoneal dialysis and 2 patiens had hemodialysis. All 
others were managed conservatively.  Two patients who had severe 
renal failure  and uremic coma died. 
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• 82 (54%) patients had CKD. The most common etiology of CKD was 
CGN(49%), followed by DN(37%) and obstructive uropathy. There was 
male preponderance in CGN and female preponderance in DN. 
• Pedal edema was commonest symptom followed by oliguria(54%). 
Anemia was present in 57% of the patients. Volume overload was 
present in >20% of patients. 
• 45% of patients had history of SHT and  20% were known cases of  
CKD. On examination 72% of the patients were hypertensive. 13% had 
malignant hypertension. 
• 61% of CKD patients were anemic. The mean serum creatinine 3.7 
mg% and  12% of the patients had hyperkalemia. 76% of patients with 
CKD had proteinuria in varying degrees.  
• 38% of patients had evidence left ventricular hypertrophy in ECG. 53% 
of patients with CKD had cardiomegaly in Chest X-Ray. 71% had 
contracted kidneys. 
• Hemodialysis was started for 6 patients. Out of these 5 were enrolled 
for renal transplantation program.. 5 patients were put on peritoneal 
dialysis. Mortality was 1%.                             
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CONCLUSIONS 
 
• ARF occurred in 46% of patients and CKD in 54% of patients. 
 
• The commonest cause of ARF is Acute diarrheal  diseases.    Infections 
(malaria, Leptospirosis, sepsis) contributed to >50% of ARF. Most of 
the patients with ARF had mild renal failure, which contributed to the 
lesser requirement of dialysis and low mortality rate.  
 
• The commonest cause of CKD was CGN (49%) followed by DN (45%). 
72% of patients had SHT. 57% had anemia. Since the prevalence of DM 
is increasing day by day, early diagnosis of DN by routine screening 
and retarding the progression by using ACEI or ARB will decrease the 
incidence of ESRD patients. 
 
• Early diagnosis of renal failure utilizing S.Creatinine ≥ 1.5 mg/dl was 
essential to diagnose and prevent complications of acute and chronic 
renal failure. 
 
 
 
PROFORMA 
 
 
Name:      Age:    Sex: 
IP No.: 
Diagnosis: 
 
Clinical Features: 
 
• Fever 
• Myalgia 
• Diarrhea 
• Vomiting 
• Giddiness 
• Altered Sensoriun 
• Headache 
• Oliguria 
• Dysuria 
• Hematuria 
• Pedal edema 
• Facial Puffiness 
• Ascites 
• Anasarca 
• Dyspnea 
• Chest pain 
• Hiccups  
• Jaundice 
• Elevated JVP 
• Anemia 
• Crackles  
• Wheeze 
• Hemiplegia 
• Dehydration 
• Pulse rate 
• Blood Pressure 
 
Laboratory Profile 
• Complete Hemogram 
• Blood Sugar 
• Blood Urea 
• Serum creatinine 
• Serum Electrolytes 
• Urinalysis 
• Liver function tests 
• ECG 
• Chest X-Ray 
• USG Abdomen 
• QBC 
• MSAT 
 
Treatment 
• IV fluids 
• Diuretics 
• Antihypertensives 
• Antibiotics 
• Peritoneal dialysis 
• Hemodialysis 
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MASTER CHART
S.No.                 Diagnosis Age Sex Fev My Dia Vom Gid ASen HA Olig Dys PE FP Asc Ana Brea CP DM DN
1 ARF/AGE 70 M 1 1 1 1 1 1
2 ARF/MALENA 50 M 1 1 1 1 1
3 ARF/AGE 65 M 1 1 1 1 1
4 ARF/AGE 19 M 1 1 1 1 1
5 ARF/AGE 37 F 1 1 1 1
6 ARF/AGE 45 M 1 1 1 1 1
7 ARF/AGE 55 F 1 1 1 1 1 1 1
8 ARF/AGE/LEPTO 29 M 1 1 1 1
9 ARF/AGE/MALARIA/LEPTO/UREMIA 55 M 1 1 1 1 1
10 ARF/AGE/R LEG CLLULITIS/DM2/SHT 45 F 1 1 1 1
11 ARF/AGE/SHT/DM2/CVA/UREMIA 70 M 1 1 1 2y
12 ARF/AGN 51 M 1 1 1 1
13 ARF/AGN 37 M 1 1 1 1 1 1 1 1 1
14 ARF/AGN/PT 60 F 1 1 1 1 1 1 1 1
15 ARF/ALC POLYNEUROPATHY 50 M
16 ARF/ALCOHOLISM/RHABDOMYOLYSIS 28 M 1 1
17 ARF/ATN/C MALARIA/PHT 60 M 1 1 1 1 1 1 1 1 1
18 ARF/BA/CAD/DCMP/PUL EDEMA 58 M 1 1 1
19 ARF/CAD/SHT/PUL EDEMA 70 M 1 1 1
20 ARF/CER MALARIA 14 M 1 1 1 1
21 ARF/COPD/COR PUL 54 M 1 1 1 1 1 1 1
22 ARF/COPD/COR PUL/SHT 60 M 1 1 1
23 ARF/CQ RES MALARIA 60 F 1 1 1 1 1 1 1 1
24 ARF/CVA/OA/NSAID 41 M
25 ARF/CVA/SHT/DM2 68 F 2y
26 ARF/CVA/SHT/PT/COPD 60 M 1
27 ARF/DM1/DKA 26 M 1 1 1 1 1 1
28 ARF/DM2/AGE 58 F 1 1 1 5y
29 ARF/DM2/CERE MALARIA 65 F 1 1 1 1 4y
30 ARF/DM2/CH PANCREATITIS 32 M 1 3y
31 ARF/DM2/DN/CCF 70 M 1 1 1 1 6m
32 ARF/DM2/DN/SHT/DKA 60 M 1 1 1 1 1 20y 2y
33 ARF/DM2/EPILEPSY/NSAID 55 M 5y
34 ARF/DM2/SHR/CCF/CID 70 F 1 1 1 5m
35 ARF/DM2/SHT/DN/CCF/GLUTEAL ABSCESS 65 M 1 1 1 1 3y
36 ARF/DM2/SHT/LEPTO 60 F 1 1 1 1 1 1 15y
37 ARF/DM2/SHT/PUO 60 M 1 1 1 1 2y
38 ARF/DM2/SHT/VBI 68 M 1 1 1 1 4y
39 ARF/DRUG INDUCED 35 M 1 1
40 ARF/FEVER 88 M 1 1 1 1 1
41 ARF/FEVER/PT 40 M 1 4y
42 ARF/HEMETEMESIS 74 M 1 1
43 ARF/ICH 70 M
44 ARF/LEPTOSPIROSIS 38 M 1 1
45 ARF/LEPTOSPIROSIS 70 M 1 1 1
46 ARF/LEPTOSPIROSIS 14 F 1 1 1 1 1 1 1 1
47 ARF/LRI/UTI 46 M 1 1 1 1
48 ARF/LVF/PUL EDEMA 8 F 1
49 ARF/LVH/SHT 67 M 1 1 1 1 1
50 ARF/MALARIA 30 M 1 1 1 1
51 ARF/MALARIA 46 M 1 1 1
52 ARF/MALARIA/UREMIA 21 M 1 1 1
53 ARF/PEO 40 M 1 1 1 1 1
54 ARF/PL EFFU/TCC RADICAL CYSTECTOMY 68 M 1 1
55 ARF/PUO 45 F 1 1 1
56 ARF/PUO 30 M 1 1
57 ARF/PUO 38 M 1 1 1
58 ARF/PUO 52 M 1 1 1 1 1 1 1 1
59 ARF/PUO/DM2 35 M 1 1 1 7y
60 ARF/PUO/SEIZURES 70 M 1
61 ARF/PUO/VBI/C SPONDY 85 M 1 1
62 ARF/PYOPNEUMOTHORAX 62 M 1 1
63 ARF/R LEG CELLULITIS/MET ENCEPHALOPATHY 70 M 1
64 ARF/RHD/CCF 42 F 1 1
65 ARF/RHD/CCF 45 M 1 1 1 1
66 ARF/SHT/CVA/KEROSENE POISONING/DM2 /AGE 49 M 1 1
67 ARF/SHT/DM2/AGE/ OLD CVA 68 M 1 1 1 5y
68 ARF/SHT/LVF 70 M 1 1 1 1 1
69 ARF/SYM POLYARTHRITIS/OA/NSAID 45 F 1 1 3y
70 ARF/TB 50 F 1 1
71 ARF/UTI/AC PYELONEPHRITIS 49 F 1 1 1 1
MASTER CHART
S.No.                 Diagnosis Age Sex Fev My Dia Vom Gid ASen HA Olig Dys PE FP Asc Ana Brea CP DM DN
72 CKD/CGN 40 M 1 1 1 1 1
73 CKD/CGN 38 F 1 1 1 1 1 1 1
74 CKD/ OLD PT/R PL EFFU/CGN 65 F 1 1 1
75 CKD/AS/AR/CGN 38 M 1 1 1
76 CKD/BA/ALCOHOLIC/CGN 70 M 1 1
77 CKD/CAD/SHT/CGN 71 M 1 1 1 1
78 CKD/CAD/SHT/CGN 56 M 1
79 CKD/CAD/SHT/CCF/DM2/DN 51 M 1 1 1 1
80 CKD/CAD/SHT/PUL EDEMA/CGN 45 M 1 1 1 1
81 CKD/CCF/OBS URO 58 M 1 1 1 1
82 CKD/CGN/ACUTE ON CHRONIC/DM2/DN 39 M 1 1 1 1 1
83 CKD/CVA/CAD/SHT/CGN 77 M 1
84 CKD/CVA/SHT/CGN 70 M
85 CKD/DM/DN 46 F 1 1 1 1 1 1 10y
86 CKD/DM1/DN 34 M 1 1 1 1 1 1 10y
87 CKD/DM2/DL/SHT 60 F 1 1 1 1 1 3y 1y
88 CKD/DM2/DN 55 F 1 1 1 5y 2y
89 CKD/DM2/DN 55 F 1 1 1 1 1 12y 10y
90 CKD/DM2/DN META ENCEPHALOPATHY 65 F 3y 1y
91 CKD/DM2/DN/D FOOT 73 F 1 1 1 1y
92 CKD/DM2/DN/OA HIP 65 F 1 1 1 2y 1m
93 CKD/DM2/DN/SHT/CVA 56 F 1 1 1 1 1 20y 4m
94 CKD/DM2/DN/SHT/D FOOT 60 M 1 1 1 1 1 1 10y 2y
95 CKD/DM2/DN/SHT/HYPOTHYROIDISM 57 M 1 1 1 1 1 1 1 5y
96 CKD/DM2/DN/SOL LIVER 48 M 1 1 1 8y 1y
97 CKD/DM2/SHT 65 F 1y 6m
98 CKD/DM2/SHT 55 M 1 1 1 1 1 5y 2y
99 CKD/DM2/SHT 70 F 1 1 1
100 CKD/DM2/SHT/CAD/HYPOTHYROIDISM 75 F 1 1 10y
101 CKD/DM2/SHT/CCF 51 F 1 1 1 1 1 1 1 1 20y
102 CKD/DM2/SHT/CCF/DN 50 F 1 1 1 1 1 1 1 17y 2y
103 CKD/DM2/SHT/CVA 62 F 1 1 1 10y
104 CKD/DM2/SHT/DN 78 M 1 1 1 1 1 1 5y 2y
105 CKD/DM2/SHT/DN/DR/CCF/PUL EDEMA 38 F 1 1 1 1 1 1 1 1 8y 2y
106 CKD/DM2/SHT/OB URO 70 F 1 1 1m
107 CKD/ESRD/DM2/DN 50 M 1 1 1 1 1 1 1 8y 5y
108 CKD/ESRD/PUL EDEMA/CGN 37 F 1 1 1 1 1
109 CKD/ESRD/PUL EDEMA/CGN 76 F 1 1 1 1 1 1
110 CKD/ESRD/PUL EDEMA/CGN 30 F 1 1 1 1 1 1 1
111 CKD/FEVER/CCF/OBS URO 60 M 1 1 1 1 1 1
112 CKD/LIMB GIRDLE DYSTROPHY/CGN 13 F
113 CKD/MPGN 18 F 1 1 1 1 1 1
114 CKD/MULTIINFARCT DEMENTIA/CGN 70 M 1 1
115 CKD/PNEUMONIA/CGN 50 M 1 1
116 CKD/RA/PARKINSON/CGN 74 M 1 1
117 CKD/RHT/CCF/AF/DM2/SHT/OBS URO 50 M 1 1 1 1 1y
118 CKD/SHT/CGN 70 F 1 1 1
119 CKD/SHT/CGN 70 M 1 1 1 1 1
120 CKD/SHT/DM2/DN 63 M 1 1 1 1 3m
121 CKD/SHT/CGN 36 M 1 1 1 1 1
122 CKD/SHT/CGN 35 M 1
123 CKD/SHT/CGN 43 F 1 1 1 1 1
124 CKD/SHT/CGN 21 M 1 1 1 1
125 CKD/SHT/DM2/DN 55 F 1 1 1 1 1 1 1
126 CKD/SHT/CGN 66 M 1 1
127 CKD/SHT/CGN 50 M 1 1 1 1 1 1
128 CKD/SHT/CGN 60 F 1 1 1 1 1 1
129 CKD/SHT/CGN 49 M 1 1
130 CKD/SHT/CGN 65 M 1 1 1
131 CKD/SHT/CGN 45 M 1 1 1 1 1
132 CKD/SHT/CAD/DM2/DN 62 F 1 1 1 1 1
133 CKD/SHT/CAD/BPH/HUN/OBS URO 73 M
134 CKD/SHT/CCF/CGN 68 F 1 1 1 1
135 CKD/SHT/CCF/URTICARIA/CGN 60 M 1 1 1 1 1
136 CKD/SHT/COPD/DM2 60 M 1 1 1 1
137 CKD/SHT/COPD/CCF/CAD/MD2/DN 65 M 1 1 1 1 1 1 3y
138 CKD/SHT/CVA/CAD/CGN 72 M 1 1 1 1 1
139 CKD/SHT/CVA/CAD/CGN 50 M 1
140 CKD/SHT/DM2 65 F 1 3y
141 CKD/SHT/DM2/CAD/LVF 78 F 1 12y
142 CKD/SHT/DM2/CCF 50 F 1 1 1 7y
143 CKD/SHT/DM2/DN/ D Foot 40 F 1 1 1 1 3y 2y
144 CKD/SHT/LVF/CGN 65 M 1 1 1
145 CKD/SHT/PNEUMONIA/CGN 45 M 1 1 1 1 1 1
146 CKD/U GASTROPATHY/CGN 45 M 1 1
147 CKD/UTI/OBS URO 47 M 1 1 1 1
148 CKD/UTI/OBS URO/RENAL CALCULUS 52 M
149 ACUTE ON CHRONIC CKD/AGE/CGN 31 M 1 1 1 1
150 ACUTE ON CHRONIC CKD/DM2/SHT/DN 39 F 1 1 1 1 1 1
151 ACUTE ON CHRONIC CKD/DM2/SHT/DN/PUL EDEMA 37 M 1 1 1 1
152 ACUTE ON CHRONIC CKD/SHT/CVA/CGN 50 M
153 ACUTE ON CHRONIC CKD/SHT/GTCS/CGN 82 M 1 1 1 1
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SHT CKD CAD PR Sys Dias JVP Ane Dehy Crk Stk Others  TC Hb S1 U1 5 Na1 K1 U Alb SB TP Alb USG RK
100 80 50 1 8.2 59 53 2.1 140 3.5 nil normal
90 100 70 1 5700 6 93 85 2 119 3.8 * normal
90 160 80 7500 10.4 90 82 2.6 137 3.8 nil
100 80 60 1 seizures 6200 10.4 96 78 2.2 147 3.8 trace 1.4 5.6 2.9
90 110 70 1 8.3 66 92 3.7 140 2.8 * normal
90 210 80 1 9.1 68 45 1.6 142 3.6 nil
82 100 70 1 1 8800 9.2 60 60 2.2 130 3.9 *
72 120 80 NSAID 7200 11 56 41 1.9 152 4.6 nil 0.6 6.1 normal
90 130 90 1 hiccups/jaundice 6300 5.8 156 128 3.6 139 5.2 * 1
2 y 70 120 80 1 6800 9.8 94 80 2.6 137 3 trace MRD
2y 80 110 70 1 5600 10.8 231 131 4.8 131 5.3 trace
90 140 100 1 NSAID 7000 11 89 72 2.9 148 5.7 *** 12.3 x 3.7
90 160 100 1 1 1 wheeze 11 110 123 4.6 128 4.7 nil 1 11.7
90 160 100 1 1 h uria 7100 10.8 64 84 3.2 142 4.2 ** 10.5 x 4.7
90 120 80 8000 11.8 900 53 2.1 142 4 nil 1 6.5
82 110 70 1 benzi + 6100 10.8 180 72 2.4 148 4.3 trace 0.9 7.2 3.5 MRD
80 110 70 1 6300 9 124 50 1.8 134 3.4 nil 1.8 5.2 3.2 14.1 x 5.4
90 60 40 1 1 1 9200 11.8 90 43 1.6 137 4 nil
1m 90 130 80 1 6200 10.4 180 115 1.5 136 3.1 trace 9.8 x 4.2
88 100 70 seizures 5200 10.6 68 67 3.1 140 3.8 * 0.8 7.8 4.8 normal
6y 86 130 90 1 wheeze 7000 10.2 60 119 1.4 129 3.2 trace
5y 76 110 80 h uria 8.8 135 62 1.5 138 4 nil MRD
100 110 70 7600 8.6 255 59 1.6 134 3.2 trace 1 5.3 3.6
2y 77 150 100 1 6000 10.8 52 42 2 146 3.4 nil normal
2y 90 150 100 1 1 1 10 76 58 1.6 139 4.8 nil normal
90 100 70 1 1 seizures 5200 10.8 128 84 3.8 144 4.5 nil 9 x 3.4
86 110 70 1 5000 11.2 223 34 1.8 129 3.9 *
88 150 80 5400 8 437 40 1.5 146 4.6 nil 0.7
92 140 90 1 4800 8.5 80 84 2.4 130 4.3 trace
80 130 90 6000 10.8 200 23 1.5 141 4.3 * 1.2 7.2 3.3 HUN
100 100 80 1 1 8000 7.6 270 164 3 133 4.3 trace
84 160 90 1 1 9.3 198 93 1.8 126 4.1 ****
88 100 70 1 seizures/jaundice 9 277 48 1.9 142 4.2 trace MRD
5y 1m 82 150 100 1 1 1 6800 8.2 98 87 1.8 136 3.8 nil
90 170 100 1 5300 10.4 56 74 1.9 140 3.9 * 0.8 5.2 3 normal
10y 100 160 80 1 6200 10.2 101 51 2 136 4.6 nil 1 6.7 4.6
112 150 100 9200 10.6 89 49 2.3 133 4.5 * MRD
4y 76 130 80 11 164 37 1.7 140 4 nil
86 150 90 5000 7.8 120 68 7 135 3.2 trace 12 x 6 HUN
10y 88 110 70 1 6200 6.9 128 146 4.2 133 4.9 ** 1.5 7.2 4.2 10.2 x 5.6
90 80 60 1 p uria/jaundice 8800 8 355 49 1.3 126 2.3 nil 0.8 6.9 3.7
120 90 60 1 ulcer/dyspepsia 6100 10 146 106 2.1 128 3.1 nil 0.9 5.9 3.8 normal
10y 74 170 130 1 9.8 64 111 1.9 142 3.6 nil
88 120 80 jaundice 6000 10 72 45 2 140 35 trace 1.6 7 3.2 normal
1y 100 110 60 1 jaundice 7200 7.8 68 128 4 128 5.8 nil 5.6 5.8 2.8 normal
80 80 60 2800 6.8 184 84 2.2 140 5.2 nil 1 5 10.1 x 4
94 110 80 NSAID 8.6 118 49 3.5 140 3.6 trace
150 150 90 1 1 10.2 64 72 2.2 144 4.6 * 9.8
92 210 130 1 6500 10 118 57 1.5 124 2.7 trace
100 110 70 1 11.4 60 52 1.9 140 4.2 ** MRD
90 120 80 6000 8.4 96 67 1.7 133 3.6 nil 1 7.3 3.5
96 150 90 h uria 7350 8.8 125 288 17.1 151 4.6 ** 1 normal
80 100 60 1 1 h uria 8900 6.5 143 273 9.4 138 3.7 nil 0.7
100 90 70 1 7000 9 105 41 1.8 136 3.5 trace 1 6.6 4.2 9.2 x 3.6
86 90 60 1 5000 9 129 80 2.1 138 33 trace 0.6 5.9
80 100 60 7200 10.2 146 101 1.5 140 4.2 trace 1.1
90 100 70 1 10.2 60 51 3.1 138 4.1 ***
102 100 60 1 hiccups/jaundice 10.9 70 136 5.9 130 4.8 nil 4.9
88 120 90 1 wheeze 7.8 226 36 1.6 142 3.6 **
2y 90 140 90 seizures 4200 8.8 116 56 1.6 129 3.9 *
90 150 90 7000 11 104 50 1.5 138 3.8 nil
82 110 70 1 1 COPD 5250 9 97 47 2.1 129 3.8 ** 1.2 6.2 3 normal
4m 92 200 120 1 11 154 126 5.4 118 5.5 ** 0.8 MRD
80 110 70 10.8 120 54 1.8 139 4 nil
110 130 80 1 1 9700 9.4 76 56 1.8 136 4.4 nil
1y 90 140 90 1 9200 10.4 60 48 1.8 144 4.2 nil
3y 80 200 120 6400 9 240 56 1.5 139 3.8 nil
2y 100 210 100 5800 10 136 71 2 130 3.1 nil
90 120 80 6900 10.2 120 142 5.5 132 5 ** 1 7.2
102 80 60 1 8200 9 198 54 1.8 135 4.7 trace 1 7.1 3.9
90 110 80 1 1 UGI-N 6200 9 121 52 1.8 137 51 nil 0.9 10.8 x 4.6
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SHT CKD CAD PR Sys Dias JVP Ane Dehy Crk Stk Others  TC Hb S1 U1 5 Na1 K1 U Alb SB TP Alb USG RK
100 210 140 1 5800 10.9 68 128 6.2 136 3.3 * 1 7.6 3.3 8.4 x 3.7
2m 90 130 80 1 7280 8.5 62 65 2.7 131 4.8 nil 9.4 x 3.7
80 110 70 1 8.2 116 108 2.4 132 5.4 nil 8.2
70 200 100 9.2 62 98 4.6 149 4.8 * 8.4 x 3
74 90 60 1 wheeze 6100 9.5 76 60 2.4 144 4.2 nil 9.2
2y 74 170 90 1 8.5 107 78 3.5 138 4.2 * 9 x 4.3
2y 2y 80 140 90 8200 10.2 90 69 3.4 134 4 * 9 x 5
5y 140 220 110 8.8 180 76 2 140 3.8 trace 8.2 x 3.9
1y 1y 84 160 110 1 9.4 66 121 7.9 142 4.5 nil 7.6
88 140 80 7900 9.7 82 89 2.8 149 4.4 nil hydronephros
is calculus R 90 130 90 1 1 10.8 198 231 11.4 140 3.2 * 8.2
5y 100 110 70 1 1 6400 11 114 71 2.2 149 3.6 *** 10 x 4.6
6m 92 210 110 1 8.4 84 57 1.7 138 3.2 trace 7 x 4.5
89 170 100 1 9200 8 181 62 4.3 138 4.4 trace 1 6.8
96 180 90 1 1 8 107 78 3.2 145 5 * 8.8
90 210 80 1 1 jaundice 5900 9 64 98 5.8 142 2.9 * 10 x 4.6
90 130 80 1 8.6 273 78 1.6 146 3.8 ** 10.1 x 4.6
5y 90 150 70 1 9200 11.8 82 165 11.7 151 5.9 ** 9.2
82 110 70 1 1 6600 10 275 107 3.7 138 3.9 * 7.6 x 3.1
100 180 90 8200 11 108 56 1.6 142 3 ** 8.8
2y 80 150 90 1 1 7600 8.4 128 120 2.5 134 3.5 ** MRD
12y 3m 80 160 100 1 1 7600 9.8 340 71 3.3 140 3.6 *** 2.9 10.1 x 4.6
2m 2y 120 140 90 1 1 1 p uria/hiccups 7.8 93 77 2.1 142 4.9 * MRD
6y 4y 90 130 80 1 1 1 8200 7.4 183 95 7.5 130 4.6 * 0.5 8.4 2.8 9.1
72 90 60 1 7100 9.6 171 69 2.4 139 4.6 ** MRD
1y 90 190 100 1 seizures 10.2 224 60 1.8 139 3.1 * MRD
5y 80 170 80 7100 10.6 324 60 1.6 150 2.2 trace 10 x 4.6
80 150 80 1 6.2 50 77 2.2 143 4.5 * 10.1 x 4.6
10y 90 170 90 1 6000 8.4 217 59 4.1 137 3.7 * 6.6
2y 1y 92 140 90 1 1 6300 7.2 200 104 2.2 139 3.2 *** 9.8
1y 84 150 100 1 5000 10.4 176 79 1.7 126 3.8 ** 7 3.8 9.6
2y 70 210 120 4500 9 140 56 1.6 142 4.2 trace 8.3 x 4
2y 100 160 100 1 1 hiccups 4800 12 109 121 4.2 132 3.5 **** 1 10 x 5
8y 86 100 70 8600 8.7 180 135 4.6 137 4 * 0.6 6.4 3.8 normal
84 140 90 1 1 h uria 8 162 157 6.8 123 3.2 ** 1 7.1 4.2 10.1 x 5.2
5y 86 130 90 1 1 5000 6 104 77 7.2 151 5.5 trace 6.4 3.6 8.8
2y 102 170 100 1 1 7400 10.4 76 191 6.7 131 4.5 nil 0.8 6.5
5y 1y 80 180 120 1 9200 9.8 120 94 3 142 4 nil 7.8
8m 110 140 90 1 1 1 3600 4 81 221 15 122 6.1 nil 6.7 x 4.7
1m 106 100 70 1 1 6900 8 107 90 2.5 138 3.3 * 1 5.9 3.9 MRD 
calculus
78 110 80 8300 7 69 89 2.2 150 3.9 nil 0.9 7.4 x 3.2
6y 6y 2y 100 100 80 1 1 9200 8 112 52 1.7 136 4.3 nil 5.7 3.6 normal
82 110 70 1 7200 9 128 103 2.5 114 2 * 8.2
3y 80 100 60 1 1 gara 8100 10.2 62 201 4.7 138 3.8 nil 10.2
82 130 90 1 hiccups 9.8 72 146 2 138 3.8 ** 7.4 x 3.2
120 220 110 1 6700 9.2 196 53 2.1 147 2.9 nil HUN
2 m 90 210 120 6250 7 122 100 4.2 130 4.5 trace 9 x 3.1
2m 2m 80 140 90 1 hiccups 8.6 120 68 3 142 3.8 * 8.8
6m 90 180 100 1 8.1 94 140 46 122 4.2 * 7.3 x 3.8
86 150 80 1 1 10.4 98 142 5.9 139 4.9 trace 1 10
90 200 140 9.8 90 117 7.9 137 3.5 ** 10.5 x 3.9
86 200 100 1 1 5600 9.2 113 102 2.3 142 4.7 ** 9.3 x 4.2
96 140 100 1 6200 8 99 104 6 142 4.6 *** 0.9 5.7 3.7 8.2 x 3.8
6m 6m 100 200 120 1 1 7200 10.2 172 84 2.4 130 4.5 nil 1 6.4 4 4.4 x 2.7
96 180 130 1 1 1 7100 8.2 140 84 2.2 144 4.6 nil 7.7 x 3.3
92 170 100 1 6450 7.8 82 175 9 140 3.5 nil 12 x 6
6y 78 150 90 1 1 6900 8 64 60 2 142 4 nil 7.5 x 3.4
80 130 80 7100 10 80 84 1.6 140 4 trace 1 5 x 2.4
6y 72 170 100 1 1 8400 8 136 123 3.9 146 3.5 trace 1 9.3 x 4.2
2y 100 180 100 1 6100 8 190 210 13.2 148 6.7 ** 7.5 x 3.4
74 160 90 1 1 7.2 97 142 7 150 5.2 * 9.3 x 4.2
74 160 70 6000 7 131 75 1.6 152 4.2 * 0.8 6.7 4.6 9.2 x 5.2 
HUN10y 90 160 100 1 6500 9.2 138 49 2.3 136 3.5 trace 7.6 4.8 7.4 x 3.6
76 170 80 1 6100 9 109 58 2.6 149 6.4 ** 7.4 x 3 
120 220 170 1 wheeze 4800 10.2 48 44 4.1 139 4.1 * 10.5 x 4.4
6m 108 150 100 5800 9.6 276 70 2 133 3.2 ** MRD
15y 6m 90 160 100 1 1 8900 10.8 100 62 2.6 135 4.8 trace MRD
6y 4y 90 130 80 1 1 6900 7.8 108 92 2.2 140 3.8 nil 8.2 x 3
5 y 80 230 100 6.8 97 92 2.6 134 4.2 * 9.3 x 4.2
12y 2y 80 160 100 1 1 1 6300 8.4 69 31 1.6 140 3.2 ** normal
4m 80 140 90 1 9 160 76 2.3 138 3.6 * 10.2
7y 80 170 90 1 1 10.2 104 40 1.2 136 3.8 * 6.8
6m 6m 100 190 60 1 1 1 p/h uria 8.8 90 132 8.6 138 6.2 ** 0.9 7.5 x 3.4
2y 106 180 100 1 1 9.2 92 60 2.4 144 4.2 trace 8.2
88 120 80 UGI-N 7400 10.2 101 54 2.2 136 4.1 ** 6.8 x 3.3
86 130 90 siddha 6800 11.9 96 82 3.8 132 5.1 nil 0.8 7.5 4.4 7.3 x 4.4
1y 90 100 60 1 8800 8 104 116 9.8 139 4 nil HUN
80 100 70 1 wheeze 10 88 145 7.5 142 3.5 **** 11.2 x 5.3
90 100 70 8.8 80 52 1.5 128 3.4 ** 8.8
84 170 130 1 hiccups 7.8 120 60 1.6 134 4 trace 7.8
2y 80 170 90 1 1 7600 10.4 110 82 2.2 128 3.8 * 7.5 x 3.4
5y 80 180 100 1 seizures 8000 10.6 69 62 2.5 150 5.4 nil 8.7 x 3.1
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USG LK          CXR           ECG QBC MSAT                               Treatment PD HD D
normal cardiomegaly WNL cipro/metro/dopamine
normal PT WNL lasix/CQ/doxy/para/rani
NAD old ASMI cipro/metro/rani
NAD WNL neg cipro/metro/rani/CQ/doxy/dom
normal NAD WNL cipro/rani/metro/doms
NAD WNL cipro/rani/metro/doms
NAD old IWMI cipro/metro/para/rani
normal COPD CAD neg 2+ cipro/metro/rani/para/doms
NAD WNL PF 3+ CQ/para/rani/CP/dom/cefo/falci
MRD NAD WNL Cipro/Metro/IVF
pl effu poor prog R wave cipro/metro/rani/cal 1
11.5 x 5.4 NAD WNL lasix/cefo/rani
11.7 cardiomegaly WNL para/rani/amit/mixtard
10.8 x 4.7 R LL pneumonia inf wall ischemia cefo/rani/doxy/nify
cardiomegaly CAD bct/pari/rani/amtri/mixtard
MRD pul edema LVH ampi/deri/lasix/ceftri/metro
10.4 x 5.5 NAD WNL posi neg Q/para/ald/lasix/ceftri/metro/rani/blood
NAD LAFB RBBB LID ampi/deri/lasix/isdn/aldac/envas/asp
10.8 x 3.8 cardiomegaly lat wall ischemia amlo/lasix/isdn/cefo/para/rani
normal NAD WNL neg neg cefo/quinine/para/rani
COPD sinus tachy/RAD lasix/amox/rani/deri
MRD cardiomegaly p pul cipro/rani/deri/lasix/bct
NAD WNL PV Q/para/doxy/cipro/rani/doms
normal NAD LVH with strain lasix/rani
normal NAD WNL cefo/rani/deri/asp/bct
9.5 x 4.2 R UL pneumonia WNL PV 3+ CP/metro/ATT/amlo/asp
cardiomegaly sinus tachy cipro/metro/rani/omez/HA
L pl eff sinus tachy 3+ cfo/glipi/para/cq
bronchiectasis sinus tachy quinine/cefo/para/rani
HUN R LL cystic changes WNL cipro/rani/metro/doms
NAD old IWMI cipro/cefo/metro/rani/H A/lasix/envas/asp/isdn
cardiomegaly WNL ceftri/metro/doxy/lasix/rani/amlo/envas/insulin
MRD NAD WNL pheny/mnni/lasix/cefo/rani/para/HA
cardiomegaly LVH with strain ampi/aten/dom/lasix/envas/isdn
normal B pl effu WNL ceftri/para/rani/amlo/dom/met/gli
cardiomegaly WNL 2+ CQ/doxy/qui/amlo/rani/cefo/HA/dom
MRD bronchiectasis WNL neg 2+ ceftri/para/rani/amlo/dom/met/gli
WNL CAD ampi/amlo/lasix/isdn/insulin
9.4 x 5.3 HUN pneumonia WNL ceftaz/lasix/cipro/rani 2
9.8 x 4.5 NAD WNL doxy/para/CQ/dos/amlo
NAD WNL neg neg doxy/cipro/HA/CQ
normal NAD IRBBB RAD panto/blood/amox/metro/cefo/rani/meto
patchy infil old ASMI cipro/para/rani/Q/CP/asp
normal NAD LVH 3+ cp/rani/para/bct
normal cardiomegaly old ASMI neg neg CP/cefo/metro/panto/hepa/vitk/Q/rani/asp/isdn
9.2 x 4 pul edema WNL neg 3+ cipro/para/CQ/rani/dom/qui/ceftri/acyclovir
patchy infil P pulm LVH cipro/metro/amlo/rani
10.6 pul edema sinus tachy CQ/cipro/doxy/rani/para/dom
NAD WNL CQ/cipro/doxy/rani/para/dom
MRD NAD LVH Q/omez/para/doxy/pheny
NAD WNL neg neg cipro/doxy/CQ/rani/para/dom
normal NAD WNL neg qui/omez/para/doxy/pheny 1
NAD LVH with strain CQ/cipro/doxy/rani/para/dom
9 x 4 L pl effu WNL dopamine/aten/asp/rani/cefo
pl effu LVH neg neg CQ/para/rani
cardiomegaly WNL neg CP/cipro/rani/para/deri/cefo/
cardiomegaly WNL CQ/para/rani
NAD WNL neg qui/doxy/CP/rani 1 1
NAD WNL HA/cefo/para/rani/deri
bronchiectasis RAD RBBB pheny/rani/deri/amlo/lasix
NAD WNL neg seftri/CQ/para/asp/rani/amlo
normal hydropneumothorax LVH lasix/asp/isdn/
MRD NAD tall T waves dig/lasix/rani/deri/cefo/acitrom
cardiomegaly sinus tachy lasix/asp/envas/aldac/KCl
cardiomegaly P mitrale/AF dig/lasix/rani/deri/cefo/kcl/acitron
pl effu LVH with strain cefo/rani/metro/asp/lasix/amlo/NTG
NAD LVH with strain PV doxy/Q/CQ/rani/dom/amlo/prima/asp/metf/glipi
NAD CLBBB LVH with strain isdn/envas/rani/cefo/lasix
NAD WNL rani/tramadol/predni/para
PT/ILD p pul/ poor prog R wave cefo/rani/deri/cipro/E/liv52
10.9 x 5.8 NAD WNL rani/cipro/oflox/doms
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7.3 x 3.8 cardiomegaly LVH tall T waves lasix/rani/nife/cal/
6.8 x 3.2 NAD WNL lasix/amlo/cal
7.8 cardiomegaly LAD LAFB old AWMI cipro/rani/cefo/amlo/cal/lasix
7.8 x 3 cardiomegaly LVH with strain amlo/rani/lasix/cal/isdn/asp/ald
8.8 pl effu WNL cefo/rani/cal
8.7 x 4.7 NAD IWMI lasix/cefo/amlo/rani/isdn/cal
9.9 x 4.4 cardiomegaly LVH asp/amlo/aldom/isdn/aten/cal
9.4 x 4.2 cardiomegaly sinus tachy/LVH with strain lasix/amlo/rani/amox/aldom
6.7 cardiomegaly LVH lasix/ampi/rani/amlo/cal/asp 1
pul edema WNL ampi/deri/rani/asp/lasix
10 cardiomegaly B pl effu LVH lasix/deri/rani/nife cal 1
10.4 x 5.1 cardiomegaly IWMI lasix/nife/NTG/deri/rani/cefo
5.4 x 2.5 cardiomegaly LVH lasix/mannitol/asp
7.2 NAD LVH lasix/rani/cal/doms/amlo
8.4 cardiomegaly sinus tachy neg cefo/rani/amlo/cal/heparin/lasix
10.4 x 5.1 pul edema tall T waves lasix/cal/amlo/ampi/rani
10 x 4.9 NAD WNL mix/glimi/lasix/cipro
9 NAD WNL lasix/amlo/rani/doms
8.2 x 2.9 COPD sinus tachy ampi/rani/glipi/cefo/HA
8.6 cardiomegaly poor prog of R wave cefo/metro/asp/isdn/envas/lasix/amlo/HA
MRD cardiomegaly poor R wave prog lasix/cefo/rani/amlo/HA
10 x 4.9 NAD LVH cefo/ha/amlo/lasix/cal
MRD NAD LVH cefo/metro/rani/doms/amlo
9.3 cardiomegaly low voltage complexes lasix/deri/cefo/cal/rani/amlo/HA
MRD pl effu LVH cefo/rani/deri/cal/lasix/HA/I&D
MRD pneumonia sinus tachy lasix/rani/amlo/cal/OHA
10.4 x 5.1 cardiomegaly sinus brady cefo/rani/amlo/OHA/para/asp
10 x 4.9 cardiomegaly LVH rani/cepha/amlo
6.8 cardiomegaly LVH amox/nife/pheny/eltrox/rani/asp/cal
10.2 pul edema sinus tachy dig/lasix/norf/rani/HA/amlo/asp/hep
9.2 cardiomegaly WNL insulin/amlo/aldo/lasix
8.4 x 3.6 NAD LAFB LVH with  strain amlo/amox/rani/lasix/cal/HA
10.5 x 5.3 cardiomegaly/pul edema poor prog R wave cipro/cefo/metro/lasix/insulin/ amlo/isdn/asp 1
normal pneumonia WNL lasix/aten/amlo/dig/cal/HA
9.4 x 5 cardiomegaly WNL cefo/metro/amlo/actrapid
7.8 cardiomegaly CAD lasix/amlo/aldom/rani/glipi 1
7.6 NAD WNL lasix/ampi/aten/amlo/aldo/rani
7.6 cardiomegaly lat wall ischemia lasix/amlo/aten/cal/dom/rani
7.4 x 3.1 pl effu CAD lasix/deri/ampi/cal/amlo 10 1
MRD cardiomegaly low voltage complexes neg dopamine/CQ/cefo/cal/rani/deri/para/metro/qui/isdn
7.2 x 3.2 NAD WNL lasix/cal/rani
normal cardiomegaly LVH rani/deri/cefo 28
8 NAD VPD ampi/rani/bct
10 R LL pneumonia WLL cefo/cipro/amlo/rani/lasix
7.4 x 3.1 cardiomegaly WNL cefo/rani/syndopa
HUN R pl effu AF amox/rani/dig/kcl/aldac/lasix
9.2 x 39.2 x 3 R LZ Infiltrations WNL ampi/lasix/amlo/cal/aten
8.2 NAD LVH with strain lasix/amlo/asp/isdn/rani/domp/cal
8 x 3.5 cardiomegaly LVH with strain LAD amlo/anox/rani/aldo/lasix
9.4 cardiomegaly LVH with strain amlo/cal/rani/cal glu iv
10.4 x 5.1 cardiomegaly LVH with strain lasix/amlo/aldom/rani/cal
8.8 x 4.2 B pl effu low voltage complexes lasix/cal/amlo/aldom
8.1 x 3.2 NAD WNL doxy/para/rani/amlo/ca
8.1 x 4.8 cardiomegaly  pul edema LVH cefo/lasix/nife/aldo/rani/aten/ca
7.7 x 4.2 cardiomegaly LVH lasix/rani/cal/amlo
12 x 6.2 NAD LAE LVH with strain cefo/lasix/amlo/aten/rani/cal
7.4 x 3.7 NAD non prog of R wave amlo/aten/lasix
7.8 x 4 cardiomegaly LAE lasix/nife/cefo/rani
8.8 x 4.2 cardiomegaly Old ASMI ampi/lasix/deri/amlo/rani/cal
7.4 x 3.7 cardiomegaly LAE lasix/HA/calglu/rani/amlo 1
8.8 x 4.2 P Effu old asmi amlo/isdn/asp/lasix 1
9.4 x 5.2 
PROS
cardiomegaly WNL lasix/nife/isdn/asp/dig/amox
7.8 x 3.5 cardiomegaly lat wall ischemia lasix/amlo/rani/isdn
6.8 x 3.8 cardiomegaly WNL alben/amlo/lasix
6 x 3.2 B pl effu LAD LVH cefo/rani/deri/cal/nife/aldo/aten
MRD cardiomegaly inf wall ischemia neg neg cipro/doxy/isdn/envas/dig/lasix/asp/rani/dom
MRD cardiomegaly LVH with strain lasix/doxy/nife/aldo/isdn/rani/CQ 1
9.2 x 2 cardiomegaly old IWMI amlo/asp/isdn/rani/amox
8.8 x 4.2 cardiomegaly WNL ampi/rani/amlo/aten/glipi
normal cardiomegaly LVH old ASMI lasix/isdn/asp/rani/envas/NA
10.6 R pl effu LVH with strain lasix dig aldac cefo
7.2 NAD WNL cefo/metro/envas/asp/nife/rani/trental/insulin
7.4 x 3.7 cardiomegaly B ple effu LVH tall T waves lasix/rani/cal/amlo
8.6 R LL pneumonia sinus tachy cefo/lasix/rani/deri/amlo
7.7 x 3.3 emphysema LVH ampi/rani/cal/onez/doms
8.1 x 3.6 NAD tall T waves cipro/rani/cal/amlo
HUN NAD WNL cipro/cal/rani 1
11 x 5.6 cardiomegaly LVH lasix/cipro/metro
9 pl effu WNL ampi/rani/cal/deri 1
7.2 NAD lat wall ischemia lasix/nife/HA/isdn/
7.4 x 3.7 cardiomegaly tall T waves cefo/cipro/metro/rani/lasix/asp/amlo
7.9 x 4 NAD LVH with strain pheny/lasix/rani/amlo/cal
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FIGURE 2 
 
ETIOLOGY OF ARF WITH FEVER 
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FIGURE 3 
 
BLOOD UREA IN ARF  
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FIGURE 4 
 
SERUM CREATININE IN ARF
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SEX DISTRIBUTION IN CGN & DN
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CLINICAL FEATURES OF CKD 
 
FIGURE 8 
 
SYMPTOMS
70
54
49
41
35
29
17
10 6 2
0
10
20
30
40
50
60
70
80
PE
DA
L E
DE
MA
OL
IGU
RIA
DY
SP
NE
A
FA
CIA
L P
UF
FIN
ES
S
GID
DIN
ES
S
VO
MI
TIN
G
CH
ES
T P
AIN
DY
SU
RIA
HIC
CU
PS
HE
MA
TU
RIA
%
 
 
 
FIGURE 9 
SIGNS
57
30
21 18 15
6
0
10
20
30
40
50
60
AN
EM
IA
CR
AC
KL
ES
AS
CIT
ES
RA
ISE
D J
VP
AN
AS
AR
CA
HE
MI
PL
EG
IA
%
 
 
 
 
